



(51) International Patent Classification:

C07K 16/28 (2006.01) C12N 15/13 (2006.01)
A61K 39/395 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2020/058303

(22) International Filing Date:

07 September 2020 (07.09.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201910863109.0 12 September 2019 (12.09.2019) CN

(71) Applicant: **BIOTHEUS INC.** [CN/CN]; 10B, Building 4, No 1 Keji 7th Road, Tangjiawan Town, Xiangzhou District, Zhuhai, Guangdong 519080 (CN).

(72) Inventors: **XU, Yifeng**; 10B, Building 4, No 1 Keji 7th Road, Tangjiawan Town, Xiangzhou District, Zhuhai, Guangdong 519080 (CN). **ZHAI, Tianhang**; 10B, Building 4, No 1 Keji 7th Road, Tangjiawan Town, Xiangzhou District, Zhuhai, Guangdong 519080 (CN). **YUAN, Zhijun**; 10B, Building 4, No 1 Keji 7th Road, Tangjiawan Town, Xiangzhou District, Zhuhai, Guangdong 519080 (CN). **TSUN, Andy**; 10B, Building 4, No 1 Keji 7th Road, Tangjiawan Town, Xiangzhou District, Zhuhai, Guangdong 519080 (CN). **SUN, Tsoyue Joanne**; 10B, Building 4, No 1 Keji 7th Road, Tangjiawan Town, Xiangzhou District, Zhuhai,

Guangdong 519080 (CN). **HUANG, Weifeng**; 10B, Building 4, No 1 Keji 7th Road, Tangjiawan Town, Xiangzhou District, Zhuhai, Guangdong 519080 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-PD-L1 SINGLE-DOMAIN ANTIBODY AND DERIVATIVES AND USE THEREOF

Effect of PM8001 and M7824 on the tumor growth of h-PD-L1 K1MC38 tumor cell in h-PD-L1 KI C57BL/6 mice




FIG. 20

(57) Abstract: Provided is a complementary determining region (CDR) of a VHH chain of an anti-PD-L1 single-domain antibody, wherein the CDR of the VHH chain includes the following: CDR1 with an amino acid sequence as shown in SEQ ID NO:5n+1; CDR2 with an amino acid sequence as shown in SEQ ID NO:5n+2, or CDR2 with an amino acid sequence having an sequence identity of greater than 85% with a sequence as shown in SEQ ID NO:2; and CDR3 with an amino acid sequence as shown in SEQ ID NO: 5n+3; wherein, each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.



Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

ANTI-PD-L1 SINGLE-DOMAIN ANTIBODY AND DERIVATIVES AND USE THEREOF

TECHNICAL FIELD

The present application relates to the technical fields of biomedicine or biopharmacy,
5 and in particular to an anti-PD-L1 single-domain antibody and derivatives and use thereof.

BACKGROUND

Programmed death 1 ligand 1 (PD-L1), also known as CD274, is a member of the B7
family and a ligand for PD-1. PD-L1 is a type I transmembrane protein consisting a total of
290 amino acids, including one IgV-like region, one IgC-like region, one transmembrane
10 hydrophobic region and one intracellular region composed of 30 amino acids.

PD-L1 has an effect of negatively regulating immune responses. It is found through
studies that PD-L1 is mainly expressed in activated T cells, B cells, macrophages, dendritic
cells, and the like. In addition to lymphocytes, PD-L1 is also expressed in endothelial cells
of many other tissues such as the thymus, heart, placenta and the like, and various non-
15 lymphoid systems such as melanoma, liver cancer, gastric cancer, renal cell carcinoma,
ovarian cancer, colon cancer, breast cancer, esophageal cancer, head and neck cancer and the
like. PD-L1 has certain versatility in regulating autoreactive T and B cells and immune
tolerance, and plays a role in T and B cell response in peripheral tissues. The high expression
of PD-L1 on tumor cells is related to the poor prognosis of cancer patients.

20 Programmed death-1 (PD-1) combined with PD-L1, also known as CD279, is a member
of the B7-CD28 superfamily. The cytoplasmic region of CD279 contains two tyrosine
residues, one near the N-terminal is located in an immunoreceptor tyrosine-based inhibitory
motif (ITIM), and the other near the C-terminal is located in an immunoreceptor tyrosine-
based switch motif (ITSM). PD-1 is mainly expressed on surfaces of activated T lymphocytes,
25 B lymphocytes and macrophages. Under normal circumstances, PD-1 can inhibit the function
of T lymphocytes and promote the function of Treg cells, thereby inhibiting autoimmune
responses and preventing the occurrence of autoimmune diseases. However, in the
development of tumors, the binding of PD-L1 expressed by tumor cells to PD-1 can promote

the immune escape of tumors by inhibiting lymphocytes. The binding of PD-L1 to PD-1 may cause a variety of biological changes and immune regulation, such as inhibiting the proliferation and activation of lymphocytes, inhibiting the differentiation of CD4+ T cells into Th1 and Th17 cells and inhibiting the release of inflammatory cytokines.

5 The successful application of monoclonal antibodies in cancer diagnostics and targeted therapy has launched a revolution in tumor therapy. Traditional monoclonal antibodies (150kD) have a high molecular mass that may hinder their propensity to penetrate through tissues, resulting in low effective concentrations in tumors and insufficient therapeutic effects. . In addition, long development periods, high production costs, insufficient stability
10 and many other factors of traditional antibodies limit their clinical application and popularization.

Single-domain antibodies are currently the smallest antibody molecules, and the molecular weight (without Fc) is 1/10 of that of ordinary antibodies. In addition to the antigen reactivity of monoclonal antibodies, single-domain antibodies also have unique functional
15 characteristics, such as a low molecular weight, high stability, good solubility, easy expression, high tissue penetrability, simple humanization and low preparation costs, which may overcome the shortcomings of traditional antibodies.

However, there is still a lack of satisfactory single-domain antibodies against PD-L1 in the field. Therefore, there is an urgent need in this field to develop specific single-domain
20 antibodies which are effective against PD-L1.

SUMMARY

The objective of the present application is to provide a class of specific single-domain antibodies which are effective against PD-L1.

25 In a first aspect of the present application, a complementarity determining region (CDR) of a VHH chain of an anti-PD-L1 single-domain antibody is provided. The CDR of the VHH chain consists of the following:

CDR1 with an amino acid sequence as shown in SEQ ID NO: 5n+1;

CDR2 with an amino acid sequence as shown in SEQ ID NO: 5n+2, or CDR2 with an amino acid sequence having an sequence identity of greater than 85% with a sequence as shown in SEQ ID NO: 2; and

CDR3 with an amino acid sequence as shown in SEQ ID NO: 5n+3.

5 Each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.

In another preferred embodiment, n is 0 or 1.

In another preferred embodiment, the amino acid sequence of CDR2 is shown in SEQ ID NO: 2, 7, 81, 84, 87, 90, 93, or 96.

10 In another preferred embodiment, CDR1, CDR2 and CDR3 are separated by framework regions FR1, FR2, FR3 and FR4 of the VHH chain.

In a second aspect of the present application, a VHH chain of an anti-PD-L1 single-domain antibody is provided. The VHH chain of the anti-PD-L1 single-domain antibody includes the CDR1, CDR2 and CDR3 according to the first aspect of the present application.

15 In another preferred embodiment, an amino acid sequence of the VHH chain of the anti-PD-L1 single-domain antibody is shown in SEQ ID NO: 5n+4, 82, 85, 88, 91, 94 or 97.

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.

20 Any one of the amino acid sequences above also includes a derivative sequence which is obtained through addition, deletion, modification and/or substitution of 1-8 (preferably 1-5, more preferably 1-3) amino acid residues and can retain a PD-L1 binding affinity of the anti-PD-L1 single-domain antibody.

In another preferred embodiment, n is 0 or 1.

In another preferred embodiment, the amino acid sequence of the VHH chain of the anti-PD-L1 single-domain antibody is shown in SEQ ID NO: 4, 9, 82, 85, 88, 91, 94 or 97.

25 In a third aspect of the present application, an anti-PD-L1 single-domain antibody is provided. The anti-PD-L1 single-domain antibody is a single-domain antibody against a PD-L1 epitope and has the VHH chain of the anti-PD-L1 single-domain antibody according to

the second aspect of the present application.

In a fourth aspect of the present application, a polynucleotide is provided. The polynucleotide encodes a protein selected from the group of proteins including: the CDR region of the VHH chain of the anti-PD-L1 single-domain antibody according to the first
5 aspect of the present application, the VHH chain of the anti-PD-L1 single-domain antibody according to the second aspect of the present application, or the anti-PD-L1 single-domain antibody according to the third aspect of the present application.

In another preferred embodiment, the polynucleotide has an amino acid sequence as shown in SEQ ID NO: 5n, 83, 86, 89, 92, 95 or 98.

10 n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16.

In another preferred embodiment, the polynucleotide includes DNA or RNA.

In a fifth aspect of the present application, an expression vector is provided. The expression vector contains the polynucleotide according to the fourth aspect of the present application.

15 In another preferred embodiment, the expression vector also contains a nucleotide sequence encoding an Fc fragment of immunoglobulin.

In another preferred embodiment, the immunoglobulin is IgG1, IgG2, IgG3 or IgG4.

In a sixth aspect of the present application, a host cell is provided. The host cell contains the expression vector according to the fifth aspect of the present application, or a genome of
20 the host cell is integrated with the polynucleotide according to the fourth aspect of the present application.

In another preferred embodiment, the host cell includes prokaryotic cells or eukaryotic cells.

In another preferred embodiment, the host cell is selected from the group of Escherichia
25 coli, yeast cells and mammalian cells.

In a seventh aspect of the present application, a method of producing an anti-PD-L1 single-domain antibody is provided, which includes the steps of:

(a) culturing the host cell according to the sixth aspect of the present application under conditions suitable for the production of single-domain antibodies, and thereby obtaining a culture containing the anti-PD-L1 single-domain antibody; and

(b) isolating or recovering the anti-PD-L1 single-domain antibody from the culture.

5 In another preferred embodiment, the anti-PD-L1 single-domain antibody has an amino acid sequence as shown in SEQ ID NO: 5n+4, 82, 85, 88, 91, 94 or 97.

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.

In an eighth aspect of the present application, a single-domain antibody fusion protein is provided. The single-domain antibody fusion protein has a structure as shown in formula I
10 from N-terminal to C-terminal:

Z1-Z2-L-Z3 (Formula I)

In the formula,

Z1 is the VHH chain of the anti-PD-L1 single-domain antibody according to the second aspect of the present application;

15 Z2 is an Fc fragment of immunoglobulin;

L is a linker sequence; and

Z3 is an immunoregulatory molecule moiety.

In another preferred embodiment, the immunoglobulin is IgG1, IgG2, IgG3 or IgG4.

In another preferred embodiment, an amino acid sequence of Z2 is shown in SEQ ID
20 NO: 99.

In another preferred embodiment, the amino acid sequence of Z2 is the same or substantially same as the amino acid sequence as shown in SEQ ID NO: 99.

In another preferred embodiment, L has an amino acid sequence selected from the group including GGGGS, (GGGGS)₂, (GGGGS)₃, (GGGGS)₄, (GGGGS)₅, or a combination
25 thereof.

In another preferred embodiment, the amino acid sequence of L is shown in SEQ ID NO:

100.

In another preferred embodiment, the amino acid sequence of L is the same or substantially same as the amino acid sequence as shown in SEQ ID NO: 100.

5 In another preferred embodiment, the immunoregulatory molecule is a TGF β RII extracellular domain.

In another preferred embodiment, an amino acid sequence of Z3 is shown in SEQ ID NO: 101.

In another preferred embodiment, the amino acid sequence of Z3 is the same or substantially same as the amino acid sequence as shown in SEQ ID NO: 101.

10 In another preferred embodiment, the substantially same indicates that at most 50 (preferably 1-20, more preferably 1-10, more preferably 1-5, most preferably 1-3) amino acids are different, and the difference includes substitution, deletion or addition of amino acids.

15 In another preferred embodiment, the substantially same indicates that a sequence identity of an amino acid sequence and a corresponding amino acid sequence is at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%.

20 In another preferred embodiment, an amino acid sequence of the single-domain antibody fusion protein is shown in SEQ ID NO: 102.

In a ninth aspect of the present application, an immunoconjugate is provided. The immunoconjugate includes:

25 (a) the VHH chain of the anti-PD-L1 single-domain antibody according to the second aspect of the present application, the anti-PD-L1 single-domain antibody according to the third aspect of the present application, or the single-domain antibody fusion protein according to the eighth aspect of the present application; and

(b) a coupling moiety selected from the group including a detectable marker, a drug, a

toxin, a cytokine, a radionuclide or an enzyme.

In another preferred embodiment, the coupling moiety is a drug or a toxin.

In another preferred embodiment, the coupling moiety is a detectable marker.

In another preferred embodiment, the conjugate is selected from a fluorescent or
5 luminescent marker, a radioactive marker, a MRI (magnetic resonance imaging) or CT
(electronic computer X-ray tomography) contrast agent, or an enzymes capable of producing
a detectable product, a radionuclide, a biotoxin, a cytokine (such as IL-2 and similar), an
antibody, an antibody Fc fragment, an antibody scFv fragment, a gold nanoparticle/nanorod,
a viral particle, a liposome, a magnetic nanoparticle, a prodrug activating enzyme (such as
10 DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL)), a chemotherapeutic agent
(such as cisplatin) or any form of nanoparticle or similar.

In another preferred embodiment, the immunoconjugate contains a multivalent (such as
bivalent) VHH chain of the anti-PD-L1 single-domain antibody according to the second
aspect of the present application, the anti-PD-L1 single-domain antibody according to the
15 third aspect of the present application, or the single-domain antibody fusion protein according
to the eighth aspect of the present application.

In another preferred embodiment, the multivalent indicates that the amino acid sequence
of the immunoconjugate contains multiple repeated VHH chains of the anti-PD-L1 single-
domain antibody according to the second aspect of the present application, the anti-PD-L1
20 single-domain antibody according to the third aspect of the present application, or the single-
domain antibody fusion protein according to the eighth aspect of the present application.

In a tenth aspect of the present application, use of the anti-PD-L1 single-domain antibody
according to the third aspect of the present application or the single-domain antibody fusion
protein according to the eighth aspect of the present application is provided, which is used in
25 preparation of (a) reagents used for detecting PD-L1 molecules and (b) drugs used for treating
tumors.

In another preferred embodiment, detection includes flow cytometry and cellular
immunofluorescence detection.

In an eleventh aspect of the present application, a pharmaceutical composition is provided, which includes:

(i) the CDR of the VHH chain of the anti-PD-L1 single-domain antibody according to the first aspect of the present application, the VHH chain of the anti-PD-L1 single-domain antibody according to the second aspect of the present application, the anti-PD-L1 single-domain antibody according to the third aspect of the present application, the single-domain antibody fusion protein according to the eighth aspect of the present application, or the immunoconjugate according to the ninth aspect of the present application; and

(ii) a pharmaceutically acceptable carrier.

In another preferred embodiment, the pharmaceutical composition is in a form of injection.

In another preferred embodiment, the pharmaceutical composition is used for manufacturing a drug for treating tumor, and the tumor is selected from the group including gastric cancer, liver cancer, leukemia, kidney tumor, lung cancer, small intestinal carcinoma, bone cancer, prostate cancer, colorectal cancer, breast cancer, colon cancer, cervical cancer, lymphoma, adrenal gland tumor, bladder tumor, or a combination thereof.

In a twelfth aspect of the present application, one or more uses of the anti-PD-L1 single-domain antibody according to the third aspect of the present application or the single-domain antibody fusion protein according to the eighth aspect of the present application is provided:

- (i) for detection of a human PD-L1 molecule;
- (ii) for flow cytometry;
- (iii) for cellular immunofluorescence detection;
- (iv) for tumor treatment; and
- (v) for tumor diagnosis.

In another preferred embodiment, the use is non-diagnostic and non-therapeutic.

In a thirteenth aspect of the present application, a recombinant protein is provided. The

recombinant protein includes:

(i) a sequence of a heavy chain variable region VHH according to the second aspect of the present application, a sequence of the single-domain antibody according to the third aspect of the present application, or the single-domain antibody fusion protein according to the eighth aspect of the present application; and

(ii) an optional tag sequence assisting expression and/or purification.

In another preferred embodiment, the tag sequence includes a 6His tag, an HA tag, a Flag tag, an Fc tag, an HSA or anti-HSA antibody or single-domain antibody, or a combination thereof.

10 In another preferred embodiment, the recombinant protein specifically binds to a PD-L1 protein.

In a fourteenth aspect of the present application, use of the VHH chain according to the second aspect of the present application, the single-domain antibody according to the third aspect of the present application, the single-domain antibody fusion protein according to the eighth aspect of the present application, or the immunoconjugate according to the ninth aspect of the present application is provided, which is used in manufacture of a medicament, a reagent, a detection plate or a kit.

The reagent, the detection plate or the kit is used for detecting a PD-L1 protein in a sample.

20 The medicament is used for treating or preventing a tumor expressing the PD-L1 protein (namely PD-L1 positive).

In another preferred embodiment, the tumor includes gastric cancer, lymphoma, liver cancer, leukemia, kidney tumor, lung cancer, small intestinal carcinoma, bone cancer, prostate cancer, colorectal cancer, breast cancer, colon cancer, adrenal gland tumor, or a combination thereof.

In a fifteenth aspect of the present application, a method for detecting a PD-L1 protein in a sample is provided, which includes the steps:

(1) contacting the sample with the single-domain antibody according to the third aspect of the present application or the single-domain antibody fusion protein according to the eighth aspect of the present application; and

(2) detecting whether an antigen-antibody complex is formed or not, wherein the formation of the complex indicates the presence of the PD-L1 protein in the sample.

In another preferred embodiment, detection includes qualitative detection and quantitative detection.

In a sixteenth aspect of the present application, a method for treating a disease is provided. The method includes administering the single-domain antibody according to the third aspect of the present application, the single-domain antibody fusion protein according to the eighth aspect of the present application, or the immunoconjugate according to the ninth aspect of the present application in an effective amount to a subject in need.

In another preferred embodiment, the subject includes a mammal.

In another preferred embodiment, the mammal is a human.

It should be understood that within the scope of the present application, the technical features of the present application above and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, more contents are not repeated here.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows that single-domain antibodies of the present application can bind to a human PD-L1 protein on a cell surface, and the binding effect of a portion of the antibodies is similar to that of a positive control.

Figure 2 shows that modified single-domain antibodies can still bind to the human PD-L1 protein on the cell surface, and the binding effect of the antibodies is similar to that of a positive control.

Figure 3 shows that modified single-domain antibodies can still block the binding of the PD-L1 protein to the human PD-1 protein on the cell surface, and the blocking effect of the

antibodies is similar to that of a positive control.

Figure 4 shows that single-domain antibodies of the present application can effectively activate T cells, and the activation effect is similar to or better than that of an antibody of a positive control.

5 Figure 5 shows a schematic structural diagram of a fusion protein.

Figure 6 shows that the fusion protein of the present application can bind to the human PD-L1 protein on the cell surface.

Figure 7 shows that the fusion protein of the present application can block the binding of the PD-L1 protein to the human PD-1 protein on the cell surface, and the blocking effect
10 of an antibody is similar to that of a positive control.

Figure 8 shows that the fusion protein of the present application can bind to TGF β 1, TGF β 2 and TGF β 3.

Figure 9 shows that the fusion protein of the present application can effectively block a TGF β /SMAD signal pathway.

15 Figure 10 shows that the fusion protein of the present application can effectively activate T cells, and the activation effect is similar to or better than that of an antibody of a positive control.

Figure 11 shows that the fusion protein of the present application can effectively inhibit tumor growth in mice.

20 Figure 12 shows a photograph of the PD-L1-VHH crystal sample of the present application.

Figure 13 shows the crystal structure of the PD-L1-VHH complex of the present application (the upper structure is PD-L1 and lower structure is the VHH).

Figure 14 shows a hydrogen bond interaction interface of PD-L1-VHH of the present
25 application (the upper structure is PD-L1 and the lower structure is VHH).

Figure 15 shows a hydrophobic interaction interface of PD-L1-VHH of the present

application (the upper structure is PD-L1 and the lower structure is VHH).

Figure 16 shows the effect of different drug groups on the tumor volume of h-PD-L1 knock-in mice implanted with h-PD-L1 knock-in MC38 tumors.

Figure 17 shows pictures of tumors in different drug groups 27 days after inoculation.

5 Figure 18 shows the effect of each group of drugs on tumor weight of h-PD-L1 knock-in mice implanted with h-PD-L1 knock-in MC38 tumors.

Figure 19 shows the effect of different drug groups on body weight of h-PD-L1 knock-in mice implanted with h-PD-L1 knock-in MC38 tumors.

10 Figure 20 shows the effect of different drug groups on tumor volume of h-PD-L1 knock-in mice implanted with h-PD-L1 knock-in MC38 tumors.

Figure 21 shows pictures of tumors in different drug groups 28 days after inoculation.

Figure 22 shows the effect of each group of drugs on tumor weight of h-PD-L1 knock-in mice implanted with h-PD-L1 knock-in MC38 tumors.

15 Figure 23 shows the effect of different drug groups on body weight of h-PD-L1 knock-in mice implanted with h-PD-L1 knock-in MC38 tumors.

DETAILED DESCRIPTION

20 After extensive and in-depth research and extensive screening, the inventors developed a class of anti-PD-L1 single-domain antibodies. Experimental results show that the PD-L1 single-domain antibody and mutant derivatives thereof obtained in the present application can effectively block the interaction between PD-L1 and PD-1, and have relatively good thermal stability.

25 Specifically, the present application used a human-derived PD-L1 antigen protein for immunizing llamas to obtain high-quality immune libraries containing single-domain antibody genetic sequences. The inventors screened for single-domain antibodies with genetic sequences showing relatively high humanization levels (sequence identity > 85%)

from the immune single-domain antibody gene library. PD-L1 protein molecules were subjected to biotinylation, and the immune library containing sequence of single-domain antibodies was screened using yeast display technology, and thus genes of the candidate single-domain antibodies specific to PD-L1 were obtained. Then the obtained genes and engineered mutants thereof were transferred into Expi-CHO cells and further screened in the aspects of antibody affinity, ability to block the binding of PD-L1 to PD-1, thermal stability and activation of T cell activity to obtain a class and panel of single-domain antibodies, which can be expressed efficiently *in vitro* with high binding specificity to human PD-L1 antigen.

In addition, experimental results show that a fusion protein produced by fusing a single-domain antibody sequence (as a targeting moiety) of the present application with an IgG1 Fc fragment (as a linking moiety) and a TGF β RII extracellular domain (as an immunoregulatory molecule moiety) is highly active with PD-L1, and can effectively block the interaction between PD-L1 and PD-1, effectively block the TGF- β /SMAD signal pathway, effectively activate human T lymphocytes and effectively inhibit tumor growth in mice.

In addition, experimental results show that the single-domain antibody of the present application can significantly inhibit the growth of subcutaneously transplanted tumors and reduce tumor weight in mice. The inhibitory effect on tumor growth at the same molar dosage is higher than that of similar molecules, anti-PD-L1 single domain antibodies and TGF- β RII-Fc fusion proteins and has no apparent toxicity to animal models of diseases.

On this basis, the present application has been completed.

Single-domain antibody of the present application

As used herein, the terms "single-domain antibody of the present application", "anti-PD-L1 single-domain antibody of the present application" and "PD-L1 single-domain antibody of the present application" are used interchangeably and all refer to single-domain antibodies with specificity in recognizing and binding to PD-L1 (including human PD-L1). Single-domain antibodies with an amino acid sequence of a VHH chain as shown in SEQ ID NO: 4, 9, 82, 85, 88, 91, 94 or 97 are particularly preferred.

As used herein, the term "antibody" or "immunoglobulin" is a heterotetrameric

glycoprotein of about 150,000 daltons with the same structural characteristics, which consists of two identical light chains (L) and two identical heavy chains (H). Each light chain is linked to a heavy chain through a covalent disulfide bond, and the numbers of disulfide bonds between the heavy chains of different immunoglobulin isotypes are different. Each heavy chain and light chain also have regularly spaced intrachain disulfide bonds. Each heavy chain has a variable region (VH) at one end, followed by multiple constant regions. Each light chain has a variable region (VL) at one end and a constant region at the other end; the constant region of each light chain is relative to the first constant region of the corresponding heavy chain, and the variable region of each light chain is relative to the variable region of the corresponding heavy chain. Special amino acid residues form an interface between the variable regions of the light chain and the heavy chain.

As used herein, the terms "single domain antibody (VHH)" and "nanobody" have the same meaning, referring to cloning the variable region of the heavy chain of an antibody and constructing a single domain antibody (VHH) consisting of only one heavy chain variable region, and the single domain antibody is the smallest antigen-binding fragment with complete functions. Usually, after obtaining an antibody with naturally missing light chain and heavy chain constant region 1 (CH1), a variable region of a heavy chain of the antibody is cloned to construct a single domain antibody (VHH) consisting of only one heavy chain variable region.

As used herein, the term "variable" means that certain parts of the variable region of an antibody are different in sequence, so that the binding and specificity of various specific antibodies to specific antigens are formed. However, variability is not evenly distributed in the entire variable region of the antibody. Variability is concentrated in three fragments in the light chain and heavy chain variable regions known as CDRs or hypervariable regions. The more conserved part of the variable region is called a framework region (FR). The variable regions of the natural heavy chain and light chain each contain four FRs, which are roughly in a β -folded configuration and connected by three CDRs forming a connecting loop, and in some cases, a partial β folded structure can be formed. The CDRs in each chain are closely joined together by the FR and form an antigen binding site of an antibody together

with the CDRs of another chain (see Kabat et al., NIH Publ. No. 91-3242, Volume I, pp. 647-669 (1991)). Constant regions are not directly involved in the binding of antibodies to antigens, but they exhibit different effector functions, such as participating in antibody-dependent cytotoxicity of the antibody.

5 As known by those skilled in the art, immunoconjugates and fusion expression products include conjugates formed by binding drugs, toxins, cytokines, radionuclides, enzymes and other diagnostic or therapeutic molecules to the antibody of the present application or fragments thereof. The present application also includes a cell surface marker or antigen bound to the anti-PD-L1 protein antibody or fragments thereof.

10 As used herein, the terms "heavy chain variable region" and " V_H " are used interchangeably.

As used herein, the terms "variable region" and "complementarity determining region (CDR)" are used interchangeably.

15 In a preferred embodiment of the present application, the heavy chain variable region of an antibody includes CDRs being CDR1, CDR2 and CDR3.

In a preferred embodiment of the present application, the heavy chain of an antibody includes the above heavy chain variable region and heavy chain constant region.

20 In the present application, the terms "antibody of the present application", "protein of the present application", or "polypeptide of the present application" are used interchangeably and all refer to a polypeptide which specifically binds to the PD-L1 protein, such as a protein or polypeptide having a heavy chain variable region, which may or may not contain initiation methionine.

25 The present application also provides other proteins or fusion expression products having the antibody of the present application. Specifically, the present application includes any protein or protein conjugate and fusion expression product (namely immunoconjugate and fusion expression product) having a heavy chain containing a variable region, as long as the variable region is identical or at least 90% homologous, preferably at least 95% homologous to the heavy chain variable region of the antibody of the present application.

Generally, antigen-binding properties of an antibody can be described by three specific regions, called variable regions (CDR), located in the heavy chain variable region, separated by four framework regions (FR), and the amino acid sequences of the four FRs are relatively conservative and do not directly participate in a binding reaction. These CDRs form a circular structure and are close to each other in spatial structure due to the β folds formed by the FRs therebetween, and the CDRs on a heavy chain and the CDRs on a corresponding light chain constitute antigen binding sites of an antibody. The amino acid sequences of antibodies of the same type can be compared to determine which amino acids constitute the FR or CDR regions.

The variable regions of the heavy chains of the antibody of the present application are of particular interest, because at least some of the variable regions are involve binding to antigens. Therefore, the present application includes molecules which have the heavy chain variable regions of the antibody with CDRs, as long as the CDRs thereof have 90% homology or above (preferably 95% or above, most preferably 98% or above) with the CDRs identified here.

The present application includes not only intact antibodies, but also fusion proteins formed by fragments of immunologically active antibodies or antibodies and other sequences. Therefore, the present application also includes fragments, derivatives and analogs of the antibodies.

As used herein, the terms "fragment", "derivative" and "analog" refer to polypeptides which substantially retain the same biological function or activity as the antibodies of the present application. The polypeptide fragments, derivatives or analogs of the present application may be (i) a polypeptide in which one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) are substituted, and such substituted amino acid residues may or may not be encoded by genetic codes, (ii) a polypeptide with substitution groups in one or more amino acid residues, (iii) a polypeptide formed by fusing a mature polypeptide to another compound (such as a compound which extends the half-life of polypeptides, such as polyethylene glycol), or (iv) a polypeptide formed by fusing an additional amino acid sequence to the polypeptide sequence (such as a

leader sequence, a secretory sequence, a sequence used for purifying the polypeptide or proprotein sequence, or a fusion protein formed with the 6His tag). According to the teaching herein, these fragments, derivatives and analogs are within the scope well known to those skilled in the art.

5 The antibody of the present application refers to a polypeptide having PD-L1 protein binding activity and the CDRs above. The term also includes variant forms of polypeptides containing the CDRs above and having the same functions as the antibody of the present application. These variant forms include (but are not limited to) deletion, insertion and/or substitution of one or more (usually 1-50, preferably 1-30, more preferably 1-20, most
10 preferably 1-10) amino acids and the addition of one or more (usually within 20, preferably within 10, and more preferably within 5) amino acids at the C-terminal and/or N-terminal. For example, in this field, when amino acids with same or similar properties are used for substitution, functions of a protein are usually not changed. For another example, the addition of one or more amino acids to the C-terminal and/or N-terminal usually does not change
15 functions of a protein. The term also includes active fragments and active derivatives of the antibody of the present application.

 The variant forms of the polypeptide include homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, DNA encoded proteins which can be hybridized with coding DNA of the antibody of the present application under high or low
20 stringency conditions, and polypeptides or proteins obtained by using antiserum against the antibody of the present application.

 The present application also provides other polypeptides, such as a fusion protein containing the single-domain antibody or fragments thereof. In addition to almost full-length polypeptides, the present application also includes fragments of the single-domain antibody
25 of the present application. Generally, the fragments have at least about 50 consecutive amino acids of the antibody of the present application, preferably at least about 60 consecutive amino acids, more preferably at least about 80 consecutive amino acids, and most preferably at least about 100 consecutive amino acids.

 In the present application, "conservative variants of the antibody of the present

application" refer to polypeptides formed by substitution of at most 10, preferably at most 8, more preferably at most 5, and most preferably at most 3 amino acids with amino acids having same or similar properties in comparison with the amino acid sequence of the antibody of the present application. These conservative variant polypeptides are best
5 produced through substitution of amino acids according to Table 1.

Table 1

Initial residues	Representative substitution	Preferred substitution
Ala (A)	Val; Leu; Ile	Val
Arg (R)	Lys; Gln; Asn	Lys
Asn (N)	Gln; His; Lys; Arg	Gln
Asp (D)	Glu	Glu
Cys (C)	Ser	Ser
Gln (Q)	Asn	Asn
Glu (E)	Asp	Asp
Gly (G)	Pro; Ala	Ala
His (H)	Asn; Gln; Lys; Arg	Arg
Ile (I)	Leu; Val; Met; Ala; Phe	Leu
Leu (L)	Leu; Val; Met; Ala; Phe	Ile
Lys (K)	Arg; Gln; Asn	Arg
Met (M)	Leu; Phe; Ile	Leu
Phe (F)	Leu; Val; Ile; Ala; Tyr	Leu
Pro (P)	Ala	Ala
Ser (S)	Thr	Thr
Thr (T)	Ser	Ser
Trp (W)	Tyr; Phe	Tyr
Tyr (Y)	Trp; Phe; Thr; Ser	Phe
Val (V)	Ile; Leu; Met; Phe; Ala	Leu

The present application also provides polynucleotide molecules encoding the antibody

or fragments thereof or fusion protein thereof. The polynucleotides of the present application can be in the form of DNA or RNA. DNA forms include cDNA, genomic DNA or artificially synthetic DNA. DNA can be single-stranded or double-stranded. DNA can be coding strands or non-coding strands.

5 Polynucleotides encoding the mature polypeptides of the present application include coding sequences only encoding the mature polypeptides, coding sequences of the mature polypeptides and various additional coding sequences, and the coding sequences of the mature polypeptides (and optional additional coding sequences) as well as non-coding sequences.

10 The term "polynucleotides encoding polypeptides" may include a polynucleotide encoding the polypeptide, or a polynucleotide which also includes the additional coding and/or non-coding sequence.

The present application also relates to polynucleotides which are hybridized with the sequences above, and the identity between the two sequences is at least 50%, preferably at
15 least 70%, and more preferably at least 80%. The present application particularly relates to polynucleotides which can be hybridized with the polynucleotides of the present application under stringent conditions. In the present application, "stringent conditions" refer to: (1) hybridization and elution at relatively low ionic strength and relatively high temperature, such as $0.2 \times \text{SSC}$, 0.1% SDS and 60°C; or (2) addition of a denaturing agent during
20 hybridization, such as 50% (v/v) formamide, 0.1% calf serum/0.1% Ficoll, 42°C or similar; or (3) hybridization occurring only when the identity between two sequences is at least 90% or above, and more preferably 95% or above. In addition, a polypeptide encoded by a hybridizable polynucleotide has the same biological function and activity as a mature polypeptide.

25 A full-length nucleotide sequence of the antibody of the present application or fragments thereof can usually be obtained by a PCR amplification method, a recombination method or an artificial synthesis method. A feasible method is using artificial synthesis method to synthesize relevant sequences, especially when the fragment length is short. Usually, a fragment with a very long sequence can be obtained by first synthesizing multiple small

fragments and then linking the fragments. In addition, a coding sequence of a heavy chain and an expression tag (such as 6His) can be fused together to form a fusion protein.

Once relevant sequences are obtained, a recombination method can be used to obtain the relevant sequences in large quantities. The relevant sequences are usually cloned into a vector,
5 then transferred into cells, and then isolated from proliferated host cells by a conventional method, so as to obtain the relevant sequences. Biomolecules (nucleic acids, proteins, or similar) involved in the present application include biomolecules which exist in an isolated form.

At present, DNA sequences encoding the protein (or fragments thereof, or derivatives
10 thereof) of the present application can be obtained completely through chemical synthesis. The DNA sequences can then be introduced into various existing DNA molecules (such as vectors) and cells known in the art. In addition, mutation can also be introduced into the protein sequences of the present application through chemical synthesis.

The present application also relates to vectors containing the suitable DNA sequences
15 and suitable promoters or control sequences. These vectors can be used to transform appropriate host cells to express proteins.

The host cells can be prokaryotic cells such as bacterial cells; or lower eukaryotic cells such as yeast cells; or higher eukaryotic cells such as mammalian cells. Representative examples include *Escherichia coli*, *Streptomyces*, bacterial cells of *Salmonella typhimurium*,
20 fungal cells such as yeast, insect cells of *Drosophila* S2 or Sf9, animal cells of CHO, COS7 and 293 cells or similar.

Transformation of the host cells with recombinant DNA can be performed by conventional techniques well known to those skilled in the art. When the host cells are prokaryotes such as *Escherichia coli*, competent cells which can absorb DNA can be
25 harvested after an exponential growth phase and treated with a CaCl_2 method, and the steps used are well known in the art. Another way is to use MgCl_2 . If necessary, transformation can also be performed by an electroporation method. When the host cells are eukaryotes, the following DNA transfection methods can be selected: a calcium phosphate co-precipitation

method, conventional mechanical methods such as microinjection, electroporation, liposome packaging or similar.

Obtained transformants can be cultured by conventional methods to express polypeptides encoded by genes of the present application. According to the used host cells, a culture medium used in culture can be selected from various conventional culture mediums. Culture is carried out under conditions suitable for the growth of the host cells. After the host cells have grown to an appropriate cell density, a selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are further cultured for a period of time.

The recombinant polypeptides in the method above can be expressed in cells or on cell membranes, or secreted out of the cells. If necessary, the recombinant proteins can be separated and purified through various separation methods according to the physical, chemical and other characteristics. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to conventional renaturation treatment, treatment with a protein precipitation agent (a salting out method), centrifugation, osmotic fungus breaking, ultra-treatment, ultra-centrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography techniques and combinations of these methods.

The antibody of the present application can be used alone and can be combined or coupled with detectable markers (for diagnostic purposes), therapeutic agents, PK (protein kinase) modified moieties or any combination of these substances.

Detectable markers for diagnostic purposes include, but are not limited to fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (electronic computer X-ray tomography) contrast agents, or enzymes capable of producing detectable products.

Therapeutic agents which can be combined or coupled with the antibody of the present application include, but are not limited to: 1. radionuclides; 2. biotoxins; 3. cytokines such

as IL-2; 4. gold nanoparticles/nanorods; 5. virus particles; 6. liposomes; 7. magnetic nanoparticles; 8. prodrug activating enzymes (such as DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL)); 9. chemotherapeutics (such as cisplatin) or any form of nanoparticles or similar.

5 **Fusion protein of the present application**

As described herein, the "fusion protein of the present application" refers to a bifunctional fusion protein having both the anti-PD-L1 single-domain antibody described in the first aspect of the present application and an immunoregulatory molecule moiety.

In the present application, a fusion protein is provided, and the single-domain antibody
10 fusion protein has a structure as shown in formula I from N-terminal to C-terminal:



In the formula,

Z1 is the VHH chain of the anti-PD-L1 single-domain antibody according to the second aspect of the present application;

15 Z2 is an Fc fragment of immunoglobulin;

L is a linker sequence; and

Z3 is an immunoregulatory molecule part.

Preferably, the immunoglobulin can be IgG1, IgG2, IgG3 or IgG4.

In a preferred embodiment, the immunoglobulin is IgG1, and the amino acid sequence
20 of Z2 is shown in SEQ ID NO: 99. In other embodiments, the amino acid sequence of Z2 is the same or substantially same as the amino acid sequence as shown in SEQ ID NO: 99.

In the present application, L is a flexible amino acid linker. Preferably, L has an amino acid sequence selected from the group including GGGGS, (GGGGS)₂, (GGGGS)₃, (GGGGS)₄, (GGGGS)₅, or a combination thereof.

25 In a preferred embodiment, the amino acid sequence of L is shown in SEQ ID NO: 100. In other embodiments, the amino acid sequence of L is the same or substantially same as the

amino acid sequence as shown in SEQ ID NO: 100.

In an embodiment of the present application, the immunoregulatory molecule is a TGF β RII extracellular domain. Preferably, the amino acid sequence of Z3 is shown in SEQ ID NO: 101. In other embodiments, the amino acid sequence of Z3 is the same or
5 substantially same as the amino acid sequence as shown in SEQ ID NO: 101.

In the present application, the substantially same indicates that at most 50 (preferably 1-20, more preferably 1-10, more preferably 1-5, most preferably 1-3) amino acids are different, and the difference includes substitution, deletion or addition of amino acids.

Preferably, the substantially same indicates that the sequence identity of an amino acid
10 sequence and a corresponding amino acid sequence is at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%.

In a preferred embodiment, the amino acid sequence of a single-domain antibody fusion
15 protein is shown in SEQ ID NO: 102.

TGF β is a key inducer of Epithelial-mesenchymal-transition (EMT). At the same time, TGF β has a strong immunosuppressive effect in a tumor microenvironment, and thus has an important regulatory effect on tumor development, metastasis and drug resistance.

Therefore, in an embodiment of the present application, a TGF β receptor II is selected
20 as an immunoregulatory molecule in the fusion protein. The fusion protein of the present application has the advantages of high dual target binding affinity and specificity, and thereby further enhancing the anti-tumor immune function.

Pharmaceutical composition

The present application also provides a composition. Preferably, the composition is a
25 pharmaceutical composition, which contains the antibody or active fragments thereof or fusion protein thereof and a pharmaceutically acceptable carrier. Generally, these substances can be formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is usually about 5-8, preferably about 6-8, although the pH can be

changed according to properties of the formulated substances and disease conditions to be treated. The formulated pharmaceutical composition can be administered by conventional routes, including (but not limited to) intratumoral administration, intraperitoneal administration, intravenous administration, or topical administration.

- 5 The pharmaceutical composition of the present application can be directly used to bind PD-L1 protein molecules, and thus can be used to treat tumors. In addition, other therapeutic agents can also be used at the same time.

10 The pharmaceutical composition of the present application contains a safe and effective amount (such as 0.001-99 wt%, preferably 0.01-90 wt%, more preferably 0.1-80 wt%) of the single-domain antibody (or a conjugate thereof) of the present application and a pharmaceutically acceptable carrier or excipient. Such carrier includes (but is not limited to) saline, buffer, glucose, water, glycerol, ethanol and combinations thereof. A pharmaceutical preparation should be matched with the administration mode. The pharmaceutical composition of the present application can be prepared into an injection form, for example,
15 the pharmaceutical composition is prepared by conventional methods with physiological saline or an aqueous solution containing glucose and other adjuvants. The pharmaceutical composition such as an injection and a solution should be manufactured under sterile conditions. The dosage of active ingredients is a therapeutically effective amount, such as about 10 µg/kg body weight to about 50 mg/kg body weight per day. In addition, the
20 polypeptides of the present application can also be used with other therapeutic agents.

25 When the pharmaceutical composition is used, a safe and effective amount of the immunoconjugate is administered to a mammal, wherein the safe and effective amount is usually at least about 10 µg/kg body weight, and in most cases not higher than about 50 mg/kg body weight. Preferably, the dosage is about 10 µg/kg body weight to about 10 mg/kg body weight. Of course, factors such as the administration route and the health conditions of patients should also be considered for the specific dosage, which are within the skill range of a skilled physician.

Labelled single-domain antibody

In a preferred embodiment of the present application, the single-domain antibody contains a detectable marker. More preferably, the marker is selected from the following group of isotopes, colloidal gold markers, colored markers or fluorescent markers.

Colloidal gold labelling can be performed by methods known to those skilled in the art.

- 5 In a preferred solution of the present application, the anti-PD-L1 single-domain antibody is labelled with colloidal gold to obtain a colloidal gold labelled single-domain antibody.

The anti-PD-L1 single-domain antibody of the present application has high specificity and titer.

Detection method

- 10 The present application also relates to a method for detecting a PD-L1 protein. Steps of the method are generally as follows: obtaining a cell and/or tissue sample; dissolving the sample in a medium; and detecting the level of the PD-L1 protein in the dissolved sample.

- In the detection method of the present application, the sample used is not particularly limited, and a representative example is a sample containing cells in a cell preservation
15 solution.

Kit

- The present application also provides a kit containing the antibody (or fragments thereof) of the present application or detection plates. In a preferred embodiment of the present application, the kit further includes a container, an instruction for use, a buffer agent or
20 similar.

- The present application also provides a detection kit for detecting the level of PD-L1. The kit includes an antibody for identifying the PD-L1 protein, a lysis medium for dissolving a sample and general reagents and buffers required for detection, such as various buffers, detection markers, detection substrates, or similar. The detection kit may be an in-vitro
25 diagnostic device.

Use

As described above, the single-domain antibody of the present application has high

values in biological use and clinical use, and use of the single-domain antibody relates to the fields of diagnosis and treatment of PD-L1 related diseases, basic medical research, biological research, or similar. Preferred use is for clinical diagnosis and targeted therapy for PD-L1.

5 **The main advantages of the present application include:**

1) The single-domain antibody of the present application is highly specific to human PD-L1 protein with a correct spatial structure.

2) The single-domain antibody of the present application has high affinity.

3) The single-domain antibody of the present application is easy to produce.

10 4) The single-domain antibody can inhibit a PD-1/PD-L1 pathway on the basis of TGF- β in a targeting and tumor microenvironment, restore T cells activity, enhance immune response and more effectively improve the effect of inhibiting tumor occurrence and development.

5) The single-domain antibody of the present application has no apparent toxicity.

15 The present application will be further described below in conjunction with working examples. It should be understood that these working examples are only used to illustrate the present application and not to limit the scope of the present application. Experimental methods without specific conditions in the following working examples are usually carried out according to conventional conditions, such as conditions in Sambrook et al., *Molecular*
20 *Cloning: Laboratory Manual* (New York: Cold Spring Harbor Laboratory Press, 1989), or conditions recommended by manufacturers. Unless otherwise specified, percentages and parts are weight percentages and parts by weight.

Example 1: Construction of a single-domain antibody library

Animal immunity

25 1 mg of a human PD-L1 antigen and a Freund's adjuvant were mixed in equal volumes for immunizing two llamas once a week with a total of 4 times to stimulate B cells to express antigen-specific single-domain antibodies. After four times of immunization, 50 ml of llama

peripheral blood was extracted and separated with a lymphocyte separation solution to obtain lymphocytes. An RNA extraction reagent Trizol (purchased from Invitrogen) was used to extract total RNA. A cDNA synthesis kit (purchased from Invitrogen) was used for reverse transcription to obtain total llama cDNA.

5 Single-domain antibody gene amplification

In a first round of PCR, IgG2 and IgG3 sequences were amplified from cDNA:

Table 1. Primers for the first round of PCR

Name	Sequence (5' to 3')	SEQ ID
Upstream primer	GTCCTGGCTGCTCTTCTACAAGG	103
Downstream primer	GGTACGTGCTGTTGAACTGTTCC	104

Products of the first round of PCR were subjected to agarose gel electrophoresis, and fragments at 750 bp were recovered after gel cutting and used for a second round of VHH sequence amplification. Primers for the second round of PCR amplification were as follows:

Table 2. Primers for the second round of PCR

Name	Sequence (5' to 3')	SEQ ID
Upstream primer	CTAGTGCGGCCGCGcTGGAGACGGTGACCTGGGT	105
Downstream primer	CGCGGATCCCAGGTGCAGCTGCAGGAGTCTGGRGGAGG	106

Products of the second round of PCR were used as templates for a third round of PCR, homologous arms were added to a VHH gene, and primers for the third round of PCR amplification were as follows:

15 Table 3. Primers for the third round of PCR

Name	Sequence (5' to 3')	SEQ ID
Upstream primer	ATTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATT AGCTAAAAGAGAGGCTGAAGCACAGGTGCAGCTGCA GGAGTCTGGRGGAGG	107

Downstream primer	AGTTGTCAGTTCCTGTGCCCCCCTCCTCCCGCGCCA CCTCCGCCCCGCACCTCCGCCACCACTGGAGACGGTGA CCTGGGT	108
-------------------	---	-----

The target fragments were recovered by using a PCR purification kit (purchased from QIAGEN).

Library construction

A linearized yeast display vector and products of the third round of PCR were mixed and electrotransformed into *saccharomyces cerevisiae* (ATCC® 20828) to construct an anti-PD-L1 single-domain antibody library from two animals, and the library size was measured to 4.47×10^7 and 4.14×10^7 .

Example 2: Screening of a PD-L1 single-domain antibody

Biotinylation of human PD-L1 protein

A human PD-L1 protein was dissolved in an appropriate volume of double-distilled water, and a biotin was dissolved and mixed with the protein solution according to a product instruction of a biotin labelling kit (purchased from Thermo) and then incubated at 4°C for 2 hours. A desalting column (purchased from Thermo) was used to remove excess biotin, and pretreatment by the desalting column and collection operation of a sample were both carried out according to steps in the product instruction.

MACS enrichment of yeasts which specifically bind to PD-L1

A VHH library constructed in Example 2 was inoculated into an SD-CAA amplification culture medium (1 L of SD-CAA amplification culture medium contained 6.7 g of YNB, 5 g of casamino acids, 13.62 g of $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$, 7.44 g of NaH_2PO_4 and 2% of glucose), the number of inoculated yeast cells was greater than ten times the library capacity (initial amplification concentration was 0.5 OD₆₀₀/ml), and culture was carried out overnight at 30°C and 225 rpm. Ten times the library capacity of the yeast cells were taken and centrifuged at 3000 rpm for 5 minutes (the following centrifugation operations were the same) to remove the culture medium, the yeast cells were resuspended with an SD-CAA induction culture medium, the initial concentration was adjusted to be 0.5 OD₆₀₀/ml, and induction was carried

out overnight. The concentration of the library after induction was measured, and ten times the library capacity of the yeast cells were taken and centrifuged to remove the culture medium. The yeast cells were resuspended with 50 ml of a washing buffer (PBS + 0.5% BSA + 2 mM EDTA) and centrifuged to remove the supernatant. The yeast cells were resuspended
5 with 10 ml of the washing buffer.

A biotin-labelled PD-L1 protein (final concentration 100 mM) was added, incubated at room temperature for 30 minutes and centrifuged, and the yeast cells were collected and washed 3 times with 50 ml of the washing buffer. The yeast cells were resuspended with 5 ml of the washing buffer, 200 µl of SA magnetic beads (purchased from Miltenyi) were added,
10 and the cells were incubated upside down for 10 minutes. A mixture of the yeast and magnetic beads was washed 3 times with the washing buffer and then added into an LS column (purchased from Miltenyi). The LS column was placed on a magnetic stand and washed with the washing buffer to remove non-specifically bound yeast cells. The column was removed from the magnetic stand, and the washing buffer was added to elute the yeast. The eluted
15 yeast was centrifuged and transferred into a 200 ml SD-CAA amplification culture medium for amplification.

Florescence-activated cell sorting to obtain high-affinity yeast cells

The yeast cells enriched by MACS were inoculated into an SD-CAA amplification culture medium, and the initial amplification concentration was 0.5 OD₆₀₀/ml. Shake flask
20 culture was carried out overnight at 30°C and 225 rpm. The yeast cell were resuspended with an SD-CAA induction culture medium (1L of SD-CAA induction culture medium contains 6.7 g of YNB, 5 g of casamino acids, 13.62 g of Na₂HPO₄·12H₂O, 7.44 g of NaH₂PO₄, 2% of galactose, 2% of raffinose and 0.1% of glucose), the initial concentration was 0.5 OD₆₀₀/ml, and induction was carried out overnight. An anti-c-Myc mouse-derived antibody (purchased
25 from Thermo) diluted by 1:200 and 100 nM of biotin-labelled PD-L1 antigen were added and incubated at room temperature for 10 minutes. The yeast was washed 3 times with PBS, a goat anti-mouse IgG (H+L) Alexa Fluor Plus 488 (purchased from Invitrogen) diluted by 1:500 and a streptavidin APC-conjugated fluorescent antibody (purchased from Invitrogen) were added and incubated in the dark at 4°C for 15 minutes. 2 ml of PBS was added to

resuspend the cells, and a BD FACS Aria III instrument was used for sorting to obtain yeast which has high binding affinity to PD-L1 antigen.

Obtaining genetic sequences of PD-L1 single-domain antibody candidates

Yeast liquid with high binding ability to the PD-L1 antigen, which was obtained by
5 MACS and FACS enrichment, was cultured overnight in an SD-CAA amplification culture medium at 30°C and 225 rpm. Yeast plasmids were extracted according to operations of a yeast plasmid extraction kit (purchased from TIANGEN). The plasmids were transformed into Top10 competent cells (purchased from TIANGEN) by electrotransfer, coated on an ampicillin resistant flat plate and cultured overnight at 37°C. Single clones were taken for
10 sequencing to obtain a VHH gene sequence.

Example 3: Construction, expression and purification of a heavy chain antibody

Construction of an antibody gene into a pCDNA3.1 expression vector

A VHH gene sequence was linked to a human IgG1 (LALA mutation) Fc fragment and digested into a linearized pCDNA3.1 vector by using a homologous recombinase (purchased
15 from Vazyme) and an *EcoR I/Not I* enzyme, and the process was carried out in accordance with a product instruction. A homologous recombination product was transformed into Top10 competent cells, coated on an ampicillin resistant flat plate and cultured overnight at 37°C, and single clones were taken for sequencing.

Cell transfection

20 An ExpiCHO™ expression system kit (purchased from Thermo) was used for transferring plasmids into Expi-CHO cells, and a transfection method was in accordance with a product instruction; after the cells were cultured for 5 days, the supernatant was collected, and protein A magnetic beads (purchased from GenScript) were used for purifying the target protein according to a sorting method. The magnetic beads were resuspended with an
25 appropriate volume of binding buffer (PBS + 0.1% Tween 20, pH 7.4) (1-4 times the volume of magnetic beads) and then added into a sample to be purified, and the mixture was incubated at room temperature for 1 hour and gently shaken during the period. The sample was placed on a magnetic stand (purchased from Beaver), the supernatant was removed, and

the magnetic beads were washed 3 times with the binding buffer. 3-5 times the volume of the magnetic beads of an elution buffer (0.1M sodium citrate, pH 3.2) was added for shaking at room temperature for 5-10 minutes, the mixture was placed back on the magnetic stand, and the elution buffer was collected and transferred into a collection tube with an added
5 neutralization buffer (1M Tris, pH 8.54) and mixed uniformly.

Example 4: Binding of a purified anti-PD-L1 antibody to human PD-L1

A pCHO1.0 vector (purchased from Invitrogen) of human PD-L1 cDNA (purchased from Sino Biological) was cloned into MCS through transfection to produce CHO cells (CHO-hPD-L1 cells) overexpressing human PD-L1. The cell density of the CHO-hPD-L1
10 cells subjected to enlarge cultivation was adjusted to 2×10^6 cells/ml, and 100 μ l of the cells were added into each well of a 96-well flow plate and centrifuged for later use. A purified PD-L1 antibody was diluted with PBS, three times dilution was started for a total of 12 points when the concentration was 400 nM, and 100 μ l of the diluted sample was added into each well of the 96-well flow plate with cells, incubated at 4°C for 30 minutes and washed twice
15 with PBS. 100 μ l of goat F(ab')₂ anti-human IgG-Fc (PE) (purchased from Abcam) diluted 100 times with PBS was added into each well, incubated at 4°C for 30 minutes and washed twice with PBS. 100 μ l of PBS was added into each well for resuspending the cells, detection was carried out on a CytoFlex (Bechman) flow cytometer, and corresponding MFI was calculated.

20 In a measuring experiment according to the method above, experimental results are shown in Figure 1, all the purified samples of the present application and the CHO-hPD-L1 cells have binding activity, and the binding activity of some purified samples was similar to that of a control antibody TECENTRIQ® (atezolizumab) (ATE; recorded in US20130034559, also known as 243.55.S70).

Example 5: Affinity measurement of a PD-L1 antibody

25 ForteBio affinity measurement was performed in accordance with an existing method (Estep, P et al., solution-based measurement of high-throughput antibody-antigen affinity and epitope classification, MAb, 2013.5(2): p.270-8). In short, a sensor was equilibrated

offline in an analysis buffer for 30 minutes and then tested online for 60 seconds to establish a baseline, and a purified antibody obtained as described above was loaded online onto an AHQ sensor. Then the sensor was placed in a 100 nM PD-L1 antigen for reaction for 5 minutes and then transferred into PBS for dissociation for 5 minutes. A 1:1 combination model was used for dynamic analysis.

Table 4. Affinities of candidate molecules

Number	SEQ ID	KD(M)	Kon(1/Ms)	Koff(1/s)
C-Ye-02	14	7.98E-08	4.69E+04	3.75E-03
C-Ye-04	9	4.89E-09	1.03E+05	5.05E-04
C-Ye-06	19	1.34E-07	4.35E+04	5.81E-03
C-Ye-17	34	3.96E-07	2.58E+04	1.02E-02
C-Ye-18	4	5.39E-09	8.33E+04	4.49E-04
C-Ye-20	39	4.86E-08	9.06E+04	4.40E-03
C-Ye-24	44	1.95E-08	7.71E+04	1.51E-03
C-Ye-26	49	3.41E-08	9.41E+04	3.21E-03
C-Ye-27	54	5.79E-08	5.45E+04	3.15E-03
C-Ye-30	59	3.94E-08	5.32E+04	2.10E-03
C-Ye-32	64	4.43E-08	5.83E+04	2.58E-03
C-Ye-34	69	2.44E-08	7.81E+04	1.91E-03
C-Ye-39	74	5.03E-07	2.12E+04	1.07E-02
C-Ye-42	79	3.89E-08	5.70E+04	2.22E-03

Example 6: Gene modification of a PD-L1 antibody

In order to remove potential glycosylation sites in C-Ye-18, a CDRH2 portion of an amino acid sequence of C-Ye-18 was point-mutated into 6 forms in Table 5:

Table 5. Mutant sequences of C-Ye-18 CDR region

Number	SEQ ID	CDRH2 region
C-Ye-18	2	SINSSSSSTYYRDSVKG
C-Ye-18-1	81	SINSGSSSTYYRDSVKG

C-Ye-18-2	84	SISSSSSSTYYRDSVKG
C-Ye-18-3	87	SIGSSSSSSTYYRDSVKG
C-Ye-18-4	90	SIYSGSSSSTYYRDSVKG
C-Ye-18-5	93	SINSDSSSSTYYRDSVKG
C-Ye-18-6	96	SINSGSSSSTYYRDSVKG

In this study, IMGT (<http://www.imgt.org>) was used to evaluate the humanization level of mutant sequences of C-Ye-18 CDR regions, results are shown in Table 6, the humanization level of all C-Ye-18 mutants was higher than 87%, and the requirements of later drug development are met.

5 Table 6. Homology of mutant sequences of C-Ye-18 CDR regions and human

Number	Germline	Homology
C-Ye-18	IGHV3-74*01	87.80%
C-Ye-18-1	IGHV3-74*01	88.80%
C-Ye-18-2	IGHV3-74*01	87.80%
C-Ye-18-3	IGHV3-74*01	87.80%
C-Ye-18-4	IGHV3-74*01	87.80%
C-Ye-18-5	IGHV3-74*01	87.80%
C-Ye-18-6	IGHV3-74*01	87.80%

A protein construction and expression purification method was the same as that in Example 3, and the purity of an obtained protein was detected by HPLC. According to the HPLC method, the mobile phase was 150 mM Na₂HPO₄·12H₂O, and the pH was 7.0. Chromatographic conditions: detection wavelength 280 nm, column temperature 25°C, flow rate 0.35 ml/min, detection time 20 minutes, and a Zenix-C SEC-300 chromatographic column (SEPAX 4.6 × 300 mm, 3 μm).

10 Table 7. Purity detection results of C-Ye-10 mutant antibodies

Number	Monomer ratio (%)
C-Ye-18	90.70
C-Ye-18-1	97.40

C-Ye-18-2	96.40
C-Ye-18-3	98.50
C-Ye-18-4	73.70
C-Ye-18-5	83.00
C-Ye-18-6	95.80

Example 7: Binding of C-Ye-18 mutant samples to human PD-L1

This experiment detected the binding activity of the purified C-Ye-18 mutant samples and CHO-hPD-L1 cells. The experimental method was the same as that in Example 4. Experimental results are in Figure 2. The C-Ye-18 mutant samples and CHO-hPD-L1 cells have good binding activity, and the level was comparable to that of C-Ye-18 and a control antibody ATE.

Example 8: Affinity measurement of C-Ye-18 mutant samples

This experiment detected the binding affinity of the purified C-Ye-18 mutant samples and human PD-L1. The experimental method was the same as that in Example 5. Experimental results are shown in Table 8. The C-Ye-18 mutant samples have very good binding activity with the human PD-L1 protein.

Table 8. Affinity of C-Ye-18 mutant samples

Number	KD(M)	kon(1/Ms)	kdis(1/s)
C-Ye-18-1	4.13E-09	2.46E+05	1.02E-03
C-Ye-18-2	5.41E-09	2.34E+05	1.27E-03
C-Ye-18-3	7.03E-09	2.41E+05	1.70E-03
C-Ye-18-4	6.40E-09	2.41E+05	1.54E-03
C-Ye-18-5	4.08E-09	2.72E+05	1.11E-03
C-Ye-18-6	6.00E-09	2.32E+05	1.39E-03

Example 9: Blocking of binding of PD-L1 to PD-1 by C-Ye-18 mutant samples

A pCHO1.0 vector (purchased from Invitrogen) of human PD-L1 cDNA (purchased from Sino Biological) was cloned into MCS through transfection to produce CHO cells

(CHO-hPD -1 cells) overexpressing human PD-L1. The cell density of the CHO-hPD-1 cells subjected to enlarge cultivation was adjusted to 2×10^6 cells/ml, and 100 μ l of the cells were added into each well of a 96-well flow plate and centrifuged for later use. Purified mutant samples were diluted with PBS, three times dilution was started for a total of 12 points when the concentration was 400 nM, 60 μ l of a diluted sample was added into each well of a 96-well sample dilution plate, 60 μ l of biotinylated human PD-L1 protein (purchased from AcroBiosystems) was added into each well at the same time, the final concentration was 500 ng/ml, and the mutant samples were incubated at 4°C for 30 minutes. 100 μ l of a co-incubation sample was added into each well of the 96-well flow plate with cells, incubated at 4°C for 30 minutes and washed twice with PBS. 100 μ l of a Streptavidin, R-Phycoerythrin Conjugate (purchased from Thermo Fisher) diluted 100 times with PBS was added into each well, incubated at 4°C for 30 minutes and washed twice with PBS. 100 μ l of PBS was added into each well for resuspending the cells, detection was carried out on a CytoFlex (Beckman) flow cytometer, and corresponding MFI was calculated.

In a measuring experiment according to the method above, experimental results are shown in Figure 3, all the mutant samples of the present application can block the binding of PD-L1 to PD-1, and the blocking level was comparable to that of C-Ye-18 and a control antibody ATE.

Example 10: Thermal stability of C-Ye-18 mutant samples

DSC (Differential scanning calorimetry) was used to detect the thermal stability of different antibodies. The samples were concentrated and then diluted with PBS to 1 mg/ml, and a 5000 \times fluorescent color developing agent Cypro Orange (purchased from Bio-Rad) was diluted 50 times with ultrapure water to obtain a 100 \times fluorescent color developing agent Sypro Orange. 50 μ l of each 1mg/ml sample was taken, 10 μ l of the 100 \times fluorescent color developing agent Sypro Orange and 40 μ l of ultrapure water were added and mixed uniformly, 30 μ l of each was add into a 96-well PCR plate, and each sample was added into three replicated wells and placed into a PCR instrument. A temperature-raising program was set as follows: the constant temperature of 25°C was hold for 5 minutes, and the temperature was raised to 99°C at a speed of 0.5°C/min. After the program ends, the temperature values

of the lowest points of curves in a "Melt Curve" diagram were read, namely the T_m value of the sample. Specific results are shown in the following Table 9.

Table 9. T_m values of C-Ye-18 mutants

Number	T _m 1(°C)	T _m 2(°C)	T _m 3(°C)
C-Ye-18	53.5	67.5	82
C-Ye-18-1	60	67.5	82
C-Ye-18-2	62.5	67.5	82
C-Ye-18-3	58	67	82
C-Ye-18-4	48	66	82
C-Ye-18-5	66	66-67	82.5
C-Ye-18-6	63	67.5	82

Example 11: A mixed lymphocyte reaction experiment

5 In the present Example, a mixed lymphocyte reaction experiment (MLR) was used to detect the activity of C-Ye-18 mutant samples to activate T cells. A specific experimental method was as follows.

PBMC cells (purchased from SAILY BIO, SLB-HPB) were resuscitated, centrifuged, resuspended with 10 ml of an X-VIVO-15 culture medium (purchased from LONZA) and
 10 subjected to adherent culture in a cell incubator at 37°C for 2 hours, and nonadherent cells were removed. 10 ml of a DC culture medium was added, 10 ng/ml GM-CSF (purchased from R&D) and 20 ng/ml IL-4 were added into an X-VIVO-15 culture medium for culture for 3 days, 5 ml of the DC culture medium was added, the cells were continuously cultured for 6 days, a DC mature culture medium was added, 1000 U/ml TNF- α (purchased from
 15 R&D), 10 ng/ml IL-6 (purchased from R&D), 5 ng/ml IL-1 β (purchased from R&D) and 1 μ M PGE2 (purchased from Tocris) were added into the X-VIVO-15 culture medium, the cells were cultured for 2 days, mature DC cells were collected, and the cell density was adjusted to be 2×10^5 cells/ml with the X-VIVO-15 culture medium.

PBMC cells (purchased from SAILY BIO, SLB-HPB) from another donor were thawed,
 20 centrifuged and resuspended with 10 ml of the X-VIVO-15 culture medium. CD4⁺ T cells

were enriched with a CD4⁺ T cell sorting kit (purchased from Stemcell) and resuspended with X-VIVO-15, the cell density was adjusted to be 2×10^6 cells/ml, the CD4⁺ T cells were mixed with the collected mature DC cells at a ratio of 1:1, and 100 μ l of a mixture was added into each well of a 96-well U-shaped bottom plate.

5 The C-Ye-18 mutant samples were diluted with the X-VIVO-15 culture medium, three times dilution was started for a total of 9 points when the concentration was 200 nM, 100 μ l of the mixed cells were added into each well and cultured for 5 days, the supernatant was collected, and an ELISA (purchased from eBioscience) method was used to detect the expression amount of IFN- γ and IL2.

10 Results are shown in Figure 4, the C-Ye-18 mutant samples, C-Ye-18-1, C-Ye-18-5 and C-Ye-18-6 all show relatively good biological activity in the MLR experiment, and the activation level was similar to or superior to that of a control antibody ATE.

Example 12 Cloning and expression of a fusion protein PD-L1/TGF β RII

15 In the present Example, a TGF β RII extracellular domain (SEQ ID NO: 101) was used as an immunoregulatory molecule moiety of a fusion protein, and a PD-L1 antibody (human IgG1 Fc, LALA mutation) (C-Ye-18-5, SEQ ID: 94) was used as a targeting moiety of the fusion protein to form a PD-L1 antibody/TGF β RII extracellular region fusion protein (PM8001, SEQ ID: 102).

20 According to a molecular cloning technology, a C-terminal amino acid of a PD-L1 single-chain antibody of the present application was linked to the TGF β RII extracellular region through (G₄S)₄G and routinely expressed through an Expi-CHO expression system. An expression and purification method was the same as that in Example 3, and a fusion protein PM8001 with the structure as shown in Figure 5 was obtained.

Example 13 Binding of a PM8001 molecule to human PD-L1

25 A method for detecting the binding activity of a purified PD-L1 antibody (C-Ye-18-5, SEQ ID: 94), a PM8001 molecule, a TGF- β R2-Fc fusion protein, a positive control M7824 (WO2015/118175 A2) and a negative control IgG protein to PD-L1 on a cell surface was the same as that in Example 4. In a measuring experiment according to the method above,

experimental results are shown in Figure 6, the PM8001 molecule of the present application and the CHO-hPD-L1 cells have binding activity, and the binding activity was similar to that of the positive control molecule M7824.

Example 14 Blocking of binding of PD-L1 protein to PD-1 cells by a PM8001 molecule

A method for detecting blocking of the binding activity of PD-L1 protein to PD-1 cells by a purified PD-L1 antibody (C-Ye-18-5), a PM8001 molecule, a TGF- β R2-Fc fusion protein, a positive control M7824 and a negative control IgG protein was the same as that in Example 9. In a measuring experiment according to the method above, experimental results are shown in Figure 7, the PM8001 molecule of the present application can block the binding of PD-L1 protein to PD-1 cells, and the blocking level was comparable to that of the positive control molecule M7824.

Example 15 An ELISA level binding experiment of a PM8001 molecule and human TGF- β family protein

Human TGF- β 1 (acrobiosystems, TG1-H421), TGF- β 2 (PeproTech, 100-35B) and TGF- β 3 (PeproTech, 100-36E) protein were diluted with an ELISA coating solution and then added into an ELISA plate for coating overnight at 4°C. The coating solution was removed, 250 μ l of PBST was added into each well for washing 3 times, and the ELISA plate was blocked with 5% BSA for 1 hour at room temperature for later use. A purified PD-L1 antibody (C-Ye-18-5), a PM8001 molecule, a TGF- β R2-Fc fusion protein and a positive control M7824 were subjected to gradient dilution and then added into the blocked ELISA plate for incubation at room temperature for 2 hours. PBST was added for washing 3 times, goat anti-human Fc-HRP (abcam, ab97225) was added into each well for incubation at room temperature for 1 hour, after PBST was added for washing 3 times, an ELISA color developing solution was added and placed at room temperature for 3 minutes, an ELISA termination solution was added, and a value of absorbance at 450 nm was read.

In a measuring experiment according to the method above, experimental results are shown in Figure 8, the PM8001 molecule of the present application has relatively good

binding to human TGF- β 1 and TGF- β 3 proteins at the ELISA level and relatively weak binding activity to human TGF- β 2 protein, and the binding level was comparable to that of the positive control molecule M7824.

Example 16 An experiment of a PM8001 molecule in blocking a TGF- β /SMAD signal pathway

An appropriate amount of 293-TGF- β /SMAD effector cells were taken, inoculated on a 96-well cell culture white bottom plate and placed in an incubator with 5% CO₂ for culture overnight at 37°C. A purified PD-L1 antibody (C-Ye-18-5), a PM8001 molecule, a TGF- β R2-Fc fusion protein and a positive control M7824 were subjected to gradient dilution, mixed with TGF- β 1 (Acro Biosystems, TG1-H421) and incubated at room temperature for 30 minutes. The mixture above was added into the white bottom plate with cells for continuous culture overnight. A Bio-Glo TM reagent (Promega) was added into each hole, and a multifunctional microplate reader was used to read a fluorescence signal value.

In a measuring experiment according to the method above, experimental results are shown in Figure 9, the PM8001 molecule of the present application can block a TGF- β /SMAD signal pathway *in vitro*, and the blocking level was comparable to that of the positive control molecule M7824.

Example 17 A mixed lymphocyte reaction experiment

A method of using mixed lymphocytes to detect a purified PD-L1 antibody (C-Ye-18-5), a PM8001 molecule, a TGF- β R2-Fc fusion protein, a positive control M7824 and a negative control IgG protein in activation of human T lymphocytes was the same as that in Example 9. Results are shown in Figure 10, the PM8001 molecule of the present application shows relatively good biological activity in an MLR experiment, and the activation level was comparable to or superior to that of the positive control molecule M7824.

Example 18 Pharmacokinetic evaluation of PM8001 in mice

Six SD mice including half male and half female were used in an experiment, light and dark adjustment was carried out every 12 hours, the temperature was 24 \pm 2°C, the humidity was 40-70%, and the mice drank water and had a diet freely. The mice were purchased from

Zhejiang Weitong Lihua Experimental Technology Co., Ltd. On the day of the experiment, a PM8001 molecule was injected into the tail veins of the SD mice once at a dosage of 10 mg/Kg.

Blood collection time points: blood was collected from the jugular veins of the mice 3 minutes, 4 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 504 hours and 672 hours after administration. A whole blood sample was placed at 2-8°C for 30 minutes and centrifuged at 12000 rpm for 5 minutes, serum was collected and centrifuged at 12000 rpm for 5 minutes at 2-8°C and stored at -80°C, and the molecular weight of free PM8001 in the serum was detected by ELISA. Results are shown in Table 10.

The free state molecule of PM8001 of the present application has a half-life of about 146 hours in the SD mice.

Table 10. T1/2 of PM8001 in SD mice

Test drug	Mode of administration	T1/2
PM8001	IV	146 hours

Example 19 Study on the tumor suppression activity of PM8001

In this experiment, MC38 cells (h-PD-L1 KI MC38) expressing human PD-L1 were used for determining the anti-tumor effect of PM8001 in PD-L1 transgenic mice. Firstly, an h-PD-L1 KI MC38 tumor-bearing mouse model was established by subcutaneous inoculation. Grouping was carried out when the average tumor volume was 80-120 mm³, the mice were given with different antibodies and different dosages of treatment during single intraperitoneal injection, the tumor volumes and body weight changes of the mice of each group were monitored twice every week for a total of three weeks, the dosage and mode of administration are shown in Table 11, and the tumor volume changes of the mice are shown in Figure 11.

Table 11. An experimental scheme of the tumor suppression activity of PM8001

Group	Administration Dosage	Administration volume	Administration concentration
Negative control	N/A	10 ml/kg	N/A

M7824	24 mg/kg	10 ml/kg	2.4 mg/ml
PM8001	14.7 mg/kg	10 ml/kg	1.47 mg/ml
C-Ye-18-5	10 mg/kg	10 ml/kg	1 mg/ml
TGF- β R II-Fc	10 mg/kg	10 ml/kg	1 mg/ml
C-Ye-18-5+TGF- β R II-Fc	10 mg/kg + 10 mg/kg	10 ml/kg + 10 ml/kg	1 mg/ml + 1 mg/ml

Experimental results are shown in Figure 11. After inoculation with h-PD-L1 KI MC38, the tumor volume of the negative control group was continuously increased, the tumor growth of the TGF- β R II-Fc and C-Ye-18-5 single-use groups was inhibited, while the PM8001 group has better control of tumor growth than the TGF- β R II-Fc and C-Ye-18-5 groups, indicating that PM8001 has a significant tumor suppression efficacy, which was comparable to or even slightly superior to that of the positive control group.

Example 20 Identification of the crystal structure of a complex of PD-L1 and a single-domain antibody VHH fragment

In this experiment, an X-ray diffraction method was adopted for identifying the crystal structure of a complex of PD-L1 and a single-domain antibody VHH fragment. A human-derived PD-L1-His tag (SEQ ID: 109) was expressed by an Escherichia coli prokaryotic system. A PD-L1 single-domain antibody fusion protein (SEQ ID: 110) was expressed by a CHO system. The PD-L1 single-domain antibody fusion protein was digested and purified with an IdeS enzyme followed by a GingisKHAN enzyme, and finally a PD-L1 single-domain antibody VHH (SEQ ID: 111) was obtained. PD-L1 and VHH were mixed at a molar ratio of 1:1 to prepare a complex sample for crystallization. The purified complex was digested with carboxypeptidase B to remove the His tag of PD-L1. The complex (7.5 mg/mL) was mixed with a crystallization reagent at a ratio of 1:1 and subjected to crystal culture at 18°C. Three days later, crystals were observed under INT kit culture conditions, and the crystal morphology is shown in Figure 12.

A single crystal was selected for an X-ray diffraction experiment at Shanghai Light Source, and diffraction data with a resolution of 1.6 Å was obtained. XDS software was used for data processing. A molecular replacement method was adopted for crystal phase

identification with PD-L1 (PDB ID: 5jds) and VHH (PDB ID: 5m2j) structures as models respectively. Refmac5 was used for refining the crystal structure. COOT was used for model detection, manual reconstruction and structural verification. The complex crystal belongs to a P21 space group, and the crystal cell parameters are: $a=34.62 \text{ \AA}$, $b=97.99 \text{ \AA}$, $c=67.52 \text{ \AA}$, $\alpha=90.00^\circ$, $\beta=90.02^\circ$, $\gamma=90.00^\circ$.

The crystal structure of the PD-L1-VHH complex obtained after structural analysis is shown in Figure 13. Epitope analysis shows that a main hydrogen-bond interaction between PD-L1 and VHH is concentrated on Tyr56, Asn63, His69, Asp73, Lys75, Ser117, Gly119, Ala121 and other amino acids on PD-L1 (Figure 14). In addition, Tyr56, His69 and Tyr123 on PD-L1 and Tyr32, Trp33, Tyr35, Leu45, Trp47, Pro100 and Tyr103 on VHH constitute a hydrophobic interaction interface (Figure 15).

Example 21 The growth inhibition effect of a PM8001 injection on an h-PD-L1 knock-in MC38 model inoculated subcutaneously in h-PD-L1 knock-in C57BL/6 mice

In this study, the *in-vivo* anti-tumor effect of PM8001 (SEQ ID: 102) administered through intraperitoneal injection on an h-PD-L1 knock-in MC38 mouse colon cancer tumor-bearing model inoculated subcutaneously in h-PD-L1 knock-in C57BL/6 mice, and the safety in h-PD-L1 knock-in mice implanted with h-PD-L1 knock-in MC38 tumors were investigated.

In this study, the h-PD-L1 knock-in MC38 subcutaneous tumor-bearing model was established by subcutaneously inoculating h-PD-L1 knock-in MC38 mouse colon cancer cells into h-PD-L1 knock-in C57BL/6 mice (purchased from GemPharmatech Co, Ltd). Ten days after inoculation, the mice were divided into 5 groups (6 mice per group) according to the tumor volume and subjected to intraperitoneal injection of PBS, 14.7 mg/kg PM8001, 10 mg/kg PM8001-NSD (anti-human PD-L1 VHH), 10 mg/kg PM8001-TGF- β R2 and 24.6 mg/kg M7824 (the corresponding molar dosages of the above administration groups were the same) respectively, and administration was carried out twice at an interval of three days. The anti-tumor effect and the safety in the tumor-bearing mice of PM8001, PM8001-NSD, PM8001-TGF- β R2 and M7824 were investigated.

Figure 16 shows the effect of different drug groups on the tumor volume of h-PD-L1 knock-in mice implanted with h-PD-L1 knock-in MC38 tumors. Figure 17 shows tumor pictures of different drug groups 27 days after inoculation. The tumors of the mice in a negative control PBS group grow rapidly, the tumor volume reaches 1500 mm³ or above 27 days after inoculation (namely, the 17th day after administration), and it indicates that the tumor model in this experiment was successfully established. Compared with the negative control PBS group, the same molar dosage of PM8001, PM8001-NSD, PM8001-TGF- β R II and M7824 can inhibit tumor growth to different degrees, and TGI of the above groups on the 17th day after administration were 80%, 72%, 15% and 53% respectively; the PM8001 injection group has a higher tumor growth inhibition effect than that of PM8001-NSD, PM8001-TGF- β R II and a similar molecular group M7824. At the end of the experiment, the tumors were taken and weighed. The tumor weight in the PM8001 injection group was lower than that of PM8001-NSD, PM8001-TGF- β R II and the similar molecular group M7824. Figure 18 shows the effect of each group of drugs on tumor weight of h-PD-L1 knock-in mice implanted with h-PD-L1 knock-in MC38 tumors.

Figure 19 shows the effect of different drug groups on body weight of h-PD-L1 knock-in mice implanted with h-PD-L1 knock-in MC38 tumors. There was no abnormality in the state of the mice in each group; compared with the control group, the body weight of the mice in each administration group was not significantly reduced; at the end of the experiment, the gross anatomy of the mice in each group shows no apparent lesions in main organs, and it indicates that the used administration dosages of drugs in each group in this experiment show no apparent toxicity to the mice.

Example 22 The growth inhibition effect of different dosages of PM8001 on an h-PD-L1 knock-in MC38 model inoculated subcutaneously in h-PD-L1 knock-in C57BL/6 mice

In this study, the *in vivo* anti-tumor effect of three different dosages of PM8001 injections on an h-PD-L1 knock-in MC38 mouse colon cancer tumor-bearing model inoculated subcutaneously in h-PD-L1 knock-in C57BL/6 mice (purchased from GemPharmatech Co, Ltd), and the safety in h-PD-L1 knock-in mice implanted with h-PD-

L1 knock-in MC38 tumors were investigated.

In this study, the h-PD-L1 knock-in MC38 subcutaneous tumor-bearing model was established by subcutaneously inoculating h-PD-L1 knock-in MC38 mouse colon cancer cells into h-PD-L1 knock-in C57BL/6 mice, and this model can be used to evaluate the anti-tumor effect related to action mechanisms of test products and safety characteristics in a disease state. Seven days after inoculation, the mice were divided into 5 groups (6 mice in each group) according to the tumor volume and administered with single intraperitoneal injection of PBS, different dosages (0.3, 2.1, 14.7 mg/kg) of the PM8001 injection or 24.6 mg/kg M7824 respectively. The anti-tumor effect of different dosages of PM8001 and the safety in tumor-bearing mice were investigated and compared with the similar molecule M7824.

Figure 20 shows the effect of different drug groups on tumor volume of h-PD-L1 knock-in mice implanted with h-PD-L1 knock-in MC38 tumors. Figure 21 shows tumor pictures of different drug groups 28 days after inoculation. The tumors of the mice in a negative control PBS group grow rapidly, the tumor volume reaches 1300 mm³ or above 28 days after inoculation, and it indicates that the tumor model in this experiment was successfully established. Compared with the negative control PBS group, PM8001 can inhibit tumor growth in a dosage-dependent manner. TGIs at low, medium and high dosages of PM8001 were 31%, 76% and 93% respectively; at the same molar dosage, the tumor growth inhibition effect of the PM8001 group (14.6 mg/kg) was higher than that of the similar molecule M7824 group (24.6 mg/kg). At the end of the experiment, tumors were taken and weighed. PM8001 can reduce tumor weight in a dosage-dependent manner. At the same molar dosage, the tumor inhibition rate of the PM8001 group (14.6 mg/kg) was higher than that of the similar molecule M7824 group (24.6 mg/kg). Figure 22 shows the effect of each group of drugs on tumor weight of h-PD-L1 knock-in mice implanted with h-PD-L1 knock-in MC38 tumors.

Figure 23 shows the effect of different drug groups on body weight of h-PD-L1 knock-in mice implanted with h-PD-L1 knock-in MC38 tumors. There was no abnormality in the state of the mice in each group; compared with the control group, the body weight of the mice in each administration group was not significantly reduced; at the end of the experiment,

the gross anatomy of the mice in each group shows no apparent lesions in main organs, and it indicates that the used administration dosages of drugs in each group in this experiment show no apparent toxicity to the mice.

5 All documents mentioned in the present application are cited as references in the present application, as if each document was individually cited as a reference. In addition, it should be understood that after reading the above teaching content of the present application, those skilled in the art can make various changes or modifications to the present application, and these equivalent forms also fall within the scope defined by the appended claims of the present application.

10

Sequence information of the present application**SEQ ID NO: 1 C-Ye-18 CDR1 amino acid sequence**

GFTFSSYWMY

5

SEQ ID NO: 2 C-Ye-18 CDR2 amino acid sequence

SINSSSSSTYYRDSVKG

SEQ ID NO: 3 C-Ye-18 CDR3 amino acid sequence

10 AKDPGGYA

SEQ ID NO: 4 C-Ye-18 VHH amino acid sequenceEVQLQESGGGLVQPGGSLRLSCAASGFTFSSYWMYWLRQAPGKGLEWVSSINSSS
SSTYYRDSVKGRFTISRDNKNTLYLQMNSLKSEDNAVYYCAKDPGGYAKGQGT
15 QVTVSS**SEQ ID NO: 5 C-Ye-18 VHH nucleotide sequence**GAGGTGCAGCTGCAGGAGTCTGGAGGAGGCTTGGTGCAGCCTGGGGGGTCTCT
GCGACTCTCCTGTGCAGCCTCTGGATTACCTTCAGTAGCTACTGGATGTATTG
20 GCTCCGTCAGGCTCCAGGGAAGGGGCTCGAGTGGGTCTCATCTATTAATAGTA
GTAGTAGTAGCACATACTATCGAGACTCCGTGAAGGGCCGATTACCATCTCC
AGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGTCTGAAATCTGA
GGACACGGCCGTGTATTACTGTGCAAAAGATCCTGGTGGGTACGCCAAAGGCC
AGGGGACCCAGGTCACCGTCTCCAGT

25

SEQ ID NO: 6 C-Ye-04 CDR1 amino acid sequence

SGFTFSSYWMY

SEQ ID NO: 7 C-Ye-04 CDR2 amino acid sequence

30 SINTSSSSSTYYRDSVKG

SEQ ID NO: 8 C-Ye-04 CDR3 amino acid sequence

AKDPGGYA

SEQ ID NO: 9 C-Ye-04 VHH amino acid sequence

QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYWMYWLRQAPGKGLEWVSSINTSS
 SSTYYRDSVKGRFTISRDNANKNTLYLQMNSLKSEDTAVYYCAKDPGGYAKGQGT
 5 QVTVSS

SEQ ID NO: 10 C-Ye-04 VHH nucleotide sequence

CAGGTGCAGCTGCAGGAGTCTGGAGGAGGCTTGGTGCAGCCTGGGGGGTCTCT
 GCGACTCTCCTGTGCAGCCTCTGGATTACCTTCAGTAGCTACTGGATGTATTG
 10 GCTCCGTCAGGCTCCAGGGAAGGGGCTCGAGTGGGTCTCATCTATTAATACTA
 GTAGTAGTAGCACATACTATCGAGACTCCGTGAAGGGCCGATTACCATCTCC
 AGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGTCTGAAATCTGA
 GGACACGGCCGTGTATTACTGTGCAAAAGATCCTGGTGGGTACGCCAAAGGCC
 AGGGGACCCAGGTCACCGTCTCCAGT

15

SEQ ID NO: 11 C-Ye-02 CDR1 amino acid sequence

GRTFNNSAMGAMG

SEQ ID NO: 12 C-Ye-02 CDR2 amino acid sequence

20 TITWSSGSSFYANSVKG

SEQ ID NO: 13 C-Ye-02 CDR3 amino acid sequence

ASRKLGGVTVVTSYDF

SEQ ID NO: 14 C-Ye-02 VHH amino acid sequence

QVQLQESGGGLVQAGGSLRLSCAASGRTFNNSAMGAMGWFRQAPGKEREVATI
 TWSSGSSFYANSVKGRFTISRDNANKNTVYLQMNSLKPEDTAVYYCASRKLGGVVT
 VVTSYDFWGQGTQVTVSS

SEQ ID NO: 15 C-Ye-02 VHH nucleotide sequence

CAGGTGCAGCTGCAGGAGTCTGGGGGAGGATTGGTGCAGGCTGGGGGGCTCTCT
 GAGACTCTCCTGTGCAGCCTCTGGACGCACCTTCAATAACTCGGCCATGGGCGC
 CATGGGATGGTTCCGCCAGGCGCCAGGGAAAGAGCGTGAGTTTGTGCGGACAA
 TTACCTGGAGTAGTGGTAGCTCATTTTATGCAAACCTCCGTGAAGGGCCGATTCA
 35 CCATCTCCAGAGACAACGCCAAGAACACGGTGTATCTGCAAATGAACAGCCTG
 AAACCTGAGGACACGGCCGTTTATTACTGTGCATCACGCAAATTGGGAGGGGT

TGTAACGGTAGTTACTTCGTATGACTTCTGGGGCCAGGGGACCCAGGTCACCGT
CTCCAGT

SEQ ID NO: 16 C-Ye-06 CDR1 amino acid sequence

5 GRTFDNYAMGAMG

SEQ ID NO: 17 C-Ye-06 CDR2 amino acid sequence

TITWSSGSSFYANSVKG

10 **SEQ ID NO: 18 C-Ye-06 CDR3 amino acid sequence**

ASRKLGGVVTVVTSYDF

SEQ ID NO: 19 C-Ye-06 VHH amino acid sequence

15 QVQLQESGGGLVQPGGSLRLSCAASGRTFDNYAMGAMGWFRQAPGKEREFVATI
TWSSGSSFYANSVKGRFTISRDNKNTVYLQMNSLKPDDTAVYYCASRKLGGVVT
VVTSYDFWGQGTQVTVSS

SEQ ID NO: 20 C-Ye-06 VHH nucleotide sequence

20 CAGGTGCAGCTGCAGGAGTCTGGAGGAGGCTTGGTGCAGCCTGGGGGGTCTCT
GAGACTCTCCTGTGCAGCCTCTGGACGCACCTTCGATAACTATGCCATGGGCGC
CATGGGATGGTTCCGCCAGGCGCCAGGGAAAGAGCGTGAGTTTGTGCGGACAA
TTACCTGGAGTAGTGGTAGCTCATTTTATGCAAACTCCGTGAAGGGCCGATTCA
CCATCTCCAGAGACAACGCCAAGAACACGGTGTATCTGCAAATGAACAGCCTG
25 AAACCTGACGACACGGCCGTTTATTACTGTGCATCACGCAAATTGGGAGGGGT
TGTAACGGTAGTTACTTCGTATGACTTCTGGGGCCAGGGGACCCAGGTCACCGT
CTCCAGT

SEQ ID NO: 21 C-Ye-09 CDR1 amino acid sequence

GRTFSTYAVG

30

SEQ ID NO: 22 C-Ye-09 CDR2 amino acid sequence

GRLTWSGSRTYYADSVKG

SEQ ID NO: 23 C-Ye-09 CDR3 amino acid sequence

AADYRSNSTWSLQSPARYEN

SEQ ID NO: 24 C-Ye-09 VHH amino acid sequence

5 QVQLQESGGGLVQAGDSLGLSCTASGRTFSTYAVGWFRQAPGKGREFVGRLTWS
 GSRTYYADSVKGRFTISRDNANKNTVYLMNSLRPEDTAVYYCAADYRSNSTWSL
 QSPARYENWGQGTQVTVSS

SEQ ID NO: 25 C-Ye-09 VHH nucleotide sequence

10 CAGGTGCAGCTGCAGGAGTCTGGGGGAGGATTGGTGCAGGCTGGGGACTCTCT
 GGGACTCTCCTGTACAGCCTCTGGACGCACCTTCAGTACCTATGCCGTGGGGTG
 GTTCCGCCAGGCTCCAGGGAAGGGGCGTGAATTTGTAGGACGTCTTACATGGA
 GCGGGAGTAGAACATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCC
 AGAGACAACGCCAAGAACACGGTGTATCTGCAAATGAACAGCCTGAGACCTGA
 GGACACGGCCGTTTATTACTGTGCAGCCGACTACCGAAGTAACAGTACCTGGT
 15 CCCTGCAAAGCCCCGGCACGTTATGAAAATTGGGGCCAGGGGACCCAGGTCACC
 GTCTCCAGT

SEQ ID NO: 26 C-Ye-10 CDR1 amino acid sequence

GRTVSNYAMG
 20

SEQ ID NO: 27 C-Ye-10 CDR2 amino acid sequence

RITGSGSSTFYADSVKG

SEQ ID NO: 28 C-Ye-10 CDR3 amino acid sequence

25 AADRWRSMVTRSDPREYEN

SEQ ID NO: 29 C-Ye-10 VHH amino acid sequence

30 QVQLQESGGGLVQAGGSLRLSCVASGRTVSNYAMGWFRQAPGKEREFFVARITGS
 GSSTFYADSVKGRFTISRNNLSNTVYLMNSLKREDTAVYYCAADRWRSMVTRS
 DPREYENWGQGTQVTVSS

SEQ ID NO: 30 C-Ye-10 VHH nucleotide sequence

35 CAGGTGCAGCTGCAGGAGTCTGGAGGAGGATTGGTGCAGGCTGGGGGCTCTCT
 GAGACTCTCCTGTGTAGCCTCTGGACGCACCGTCAGTAACTATGCCATGGGGCTG
 GTTCCGCCAGGCTCCAGGGAAGGAGCGTGAGTTTGTAGCACGGATTACCGGGA

GTGGTAGTAGCACATTCTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCA
 GAAACAACCTTGTCTGAACACGGTGTATCTGCAGATGAACAGCCTGAAACGTGAG
 GACACGGCCGTTTATTACTGTGCAGCAGATCGCTGGCGTTCAATGGTGACTAGA
 TCTGACCCGAGGGAGTATGAGAACTGGGGCCAGGGGACCCAGGTCACCGTCTC
 5 CAGT

SEQ ID NO: 31 C-Ye-17 CDR1 amino acid sequence

GRTVSNYAMG

10 **SEQ ID NO: 32 C-Ye-17 CDR2 amino acid sequence**

RITGSGSSTFYADSVKG

SEQ ID NO: 33 C-Ye-17 CDR3 amino acid sequence

AADRWRSMVTRSDPREYEN

15

SEQ ID NO: 34 C-Ye-17 VHH amino acid sequence

QVQLQESGGGLVQAGGSLRLSCVASGRTVSNYAMGWFRQAPGKEREVARITGS
 GSSTFYADSVKGLFTISRNNLSNTVYLQMNSLKREDTAVYYCAADRWRSMVTRSD
 PREYENWGQGTQVTVSS

20

SEQ ID NO: 35 C-Ye-17 VHH nucleotide sequence

CAGGTGCAGCTGCAGGAGTCTGGAGGAGGATTGGTGCAGGCTGGGGGCTCTCT
 GAGACTCTCCTGTGTAGCCTCTGGACGCACCGTCAGTAACTATGCCATGGGCTG
 GTTCCGCCAGGCTCCAGGGAAGGAGCGTGAGTTTGTAGCACGGATTACCGGGA
 25 GTGGTAGTAGCACATTCTATGCAGACTCCGTGAAGGGCCTATTCACCATCTCCA
 GAAACAACCTTGTCTGAACACGGTGTATCTGCAGATGAACAGCCTGAAACGTGAG
 GACACGGCCGTTTATTACTGTGCAGCAGATCGCTGGCGTTCAATGGTGACTAGA
 TCTGACCCGAGGGAGTATGAGAACTGGGGCCAGGGGACCCAGGTCACCGTCTC
 CAGT

30

SEQ ID NO: 36 C-Ye-20 CDR1 amino acid sequence

GRTVSNYAMG

SEQ ID NO: 37 C-Ye-20 CDR2 amino acid sequence

35 RITGSGSSTFYADSVKG

SEQ ID NO: 38 C-Ye-20 CDR3 amino acid sequence

AADRWRSMVTRSYPREYEN

5 SEQ ID NO: 39 C-Ye-20 VHH amino acid sequence

QVQLQESGGGLVQAGGSLRLSCVASGRTVSNYAMGWFRQAPGKEREVVARITGS
 GSSTFYADSVKGRFTISRDNNAKNAVYLMNSLKPEDTAVYYCAADRWRSMVTRS
 YPREYENWGQGTQVTVSS

10 SEQ ID NO: 40 C-Ye-20 VHH nucleotide sequence

CAGGTGCAGCTGCAGGAGTCTGGAGGAGGATTGGTGCAGGCTGGGGGCTCTCT
 GAGACTCTCCTGTGTAGCCTCTGGACGCACCGTCAGTAACTATGCCATGGGCTG
 GTTCCGCCAGGCTCCAGGGAAGGAGCGTGAGTTTGTAGCACGGATTACCGGGA
 GTGGTAGTAGCACATTCTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCA
 15 GAGACAACGCCAAGAACGCGGTGTATCTGCAAATGAACAGCCTGAAACCTGAG
 GACACGGCCGTTTATTACTGTGCAGCAGATCGCTGGCGTTCAATGGTGACTAGA
 TCTTACCCGAGGGAGTATGAGAACTGGGGCCAGGGGACCCAGGTCACCGTCTC
 CAGT

20 SEQ ID NO: 41 C-Ye-24 CDR1 amino acid sequence

GRTVSNYAMG

SEQ ID NO: 42 C-Ye-24 CDR2 amino acid sequence

RITGSGRTTYADSVKG

25

SEQ ID NO: 43 C-Ye-24 CDR3 amino acid sequence

AADRWRSMVTRSDPREYEN

SEQ ID NO: 44 C-Ye-24 VHH amino acid sequence

30 QVQLQESGGGVVQAGDSLRLSCVASGRTVSNYAMGWFRQAPGKEREVVARITGS
 GRRTTYADSVKGRFTISRNNLSNTVYLMNSLKRDTAVYYCAADRWRSMVTRS
 DPREYENWGQGTQVTVSS

SEQ ID NO: 45 C-Ye-24 VHH nucleotide sequence

35 CAGGTGCAGCTGCAGGAGTCTGGAGGAGGTGTGGTGCAGGCTGGGGACTCTCT

GAGACTCTCCTGTGTAGCCTCTGGACGCACCGTCAGTAACTATGCCATGGGCTG
 GTTCCGCCAGGCTCCAGGGAAGGAGCGTGAGTTTGTAGCACGGATTACCGGGA
 GTGGTCGTACCACATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCA
 GAAACAACCTTGTCGAACACGGTGTATCTGCAGATGAACAGCCTGAAACGTGAG
 5 GACACGGCCGTTTATTACTGTGCAGCAGATCGCTGGCGTTCAATGGTGACTAGA
 TCTGACCCGAGGGAGTATGAGAACTGGGGCCAGGGGACCCAGGTCACCGTCTC
 CAGT

SEQ ID NO: 46 C-Ye-26 CDR1 amino acid sequence

10 GRTVSNYAMG

SEQ ID NO: 47 C-Ye-26 CDR2 amino acid sequence

RITGSGSSTFYADSVKG

15 **SEQ ID NO: 48 C-Ye-26 CDR3 amino acid sequence**

AADRWRSMVTRSDPRDYEN

SEQ ID NO: 49 C-Ye-26 VHH amino acid sequence

QVQLQESGGGLVQAGGSLRLSCVASGRVSNYAMGWFRQAPGKEREVVARITGS
 20 GSSTFYADSVKGRFTISRNNLSNTVYLMNSLKREDTAVYYCAADRWRSMVTRS
 DPRDYENWGQGTQVTVSS

SEQ ID NO: 50 C-Ye-26 VHH nucleotide sequence

CAGGTGCAGCTGCAGGAGTCTGGGGGAGGATTGGTGCAGGCTGGGGGCTCTCT
 25 GAGACTCTCCTGTGTAGCCTCTGGACGCACCGTCAGTAACTATGCCATGGGCTG
 GTTCCGCCAGGCTCCAGGGAAGGAGCGTGAGTTTGTAGCACGGATTACCGGGA
 GTGGTAGTAGCACATTCTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCA
 GAAACAACCTTGTCGAACACGGTGTATCTGCAGATGAACAGCCTGAAACGTGAG
 GACACGGCCGTTTATTACTGTGCAGCAGATCGCTGGCGTTCAATGGTGACTAGA
 30 TCTGACCCGAGGGATTATGAGAACTGGGGCCAGGGGACCCAGGTCACCGTCTC
 CAGT

SEQ ID NO: 51 C-Ye-27 CDR1 amino acid sequence

GRTFSRYAVG
 35

SEQ ID NO: 52 C-Ye-27 CDR2 amino acid sequence

AITWSGGYTTYADSVKG

SEQ ID NO: 53 C-Ye-27 CDR3 amino acid sequence

AVDTRNVIGPRAGDY

5

SEQ ID NO: 54 C-Ye-27 VHH amino acid sequence

QVQLQESGGGLVQAGGSLRLSCAASGRTFSRYAVGWFRQAPGLGRDFVAAITWS
GGYTTYADSVKGRFTISRDNKNTVYLQMNSLKPEDTAVYYCAVDTRNVIGPRA
GDYWGQGTQVTVSS

10

SEQ ID NO: 55 C-Ye-27 VHH nucleotide sequence

CAGGTGCAGCTGCAGGAGTCTGGAGGAGGATTGGTGCAGGCTGGGGGCTCTCT
GAGACTCTCCTGTGCAGCCTCTGGACGCACCTTCAGTAGGTATGCCGTGGGCTG
GTTCCGCCAGGCTCCAGGGCTGGGGCGTGACTTTGTAGCAGCTATTACCTGGAG
15 TGGTGGTTACACATACTATGCGGACTCCGTGAAGGGCCGATTCACCATCTCCAG
AGACAACGCCAAGAACACGGTGTATTTGCAAATGAACAGCCTGAAACCTGAGG
ACACGGCCGTTTATTACTGTGCAGTCGATACGAGGAATGTAATCGGCCCAAGA
GCGGGAGACTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCAGT

SEQ ID NO: 56 C-Ye-30 CDR1 amino acid sequence

GSTFSRYAVG

SEQ ID NO: 57 C-Ye-30 CDR2 amino acid sequence

AITWSGGYTTYADSVKG

25

SEQ ID NO: 58 C-Ye-30 CDR3 amino acid sequence

AVDTRNVIGPRAGDY

SEQ ID NO: 59 C-Ye-30 VHH amino acid sequence

30 QVQLQESGGGLVQAGGSLRLSCAASGSTFSRYAVGWFRQAPGLGRDFVAAITWSG
GYTTYADSVKGRFTISRDNKNTVYLQMNSLKPEDTAVYYCAVDTRNVIGPRAG
DYWGQGTQVTVSS

SEQ ID NO: 60 C-Ye-30 VHH nucleotide sequence

CAGGTGCAGCTGCAGGAGTCTGGAGGAGGATTGGTGCAGGCTGGGGGCTCTCT
 GAGACTCTCCTGTGCAGCCTCTGGAAGCACCTTCAGTAGGTATGCCGTGGGCTG
 GTTCCGCCAGGCTCCAGGGCTGGGGCGTGACTTTGTAGCAGCTATTACCTGGAG
 TGGTGGTTACACATACTATGCGGACTCCGTGAAGGGCCGATTCACCATCTCCAG
 5 AGACAACGCCAAGAACACGGTGTATTTGCAAATGAACAGCCTGAAACCTGAGG
 ACACGGCCGTTTATTACTGTGCAGTCGATACGAGGAATGTAATCGGCCCAAGA
 GCGGGAGACTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCAGT

SEQ ID NO: 61 C-Ye-32 CDR1 amino acid sequence

10 GRTFSRYAVG

SEQ ID NO: 62 C-Ye-32 CDR2 amino acid sequence

AITWSGGYTTYADSVKG

15 **SEQ ID NO: 63 C-Ye-32 CDR3 amino acid sequence**

AVDTRNVIGPRAGDY

SEQ ID NO: 64 C-Ye-32 VHH amino acid sequence

QVQLQESGGGLVQAGGSLRLSCAASGRTFSRYAVGWFRQAPGLGRDFVAAITWS
 20 GGYTTYADSVKGRFTISRDNANKNTIYLQMNSLVNEDTGVVYCAVDTRNVIGPRAG
 DYWGQGTQVTVSS

SEQ ID NO: 65 C-Ye-32 VHH nucleotide sequence

CAGGTGCAGCTGCAGGAGTCTGGAGGAGGATTGGTGCAGGCTGGGGGCTCTCT
 25 GAGACTCTCCTGTGCAGCCTCTGGACGCACCTTCAGTAGGTATGCCGTGGGCTG
 GTTCCGCCAGGCTCCAGGGCTGGGGCGTGACTTTGTAGCAGCTATTACCTGGAG
 TGGTGGTTACACATACTATGCGGACTCCGTGAAGGGCCGATTCACCATCTCCAG
 AGACAACGCCAAGAACACGATCTATCTCCAAATGAACAGCCTGAACGTTGAGG
 ACACGGGCGTTTATTACTGCGCAGTCGATACGAGGAATGTAATCGGCCCAAGA
 30 GCGGGAGACTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCAGT

SEQ ID NO: 66 C-Ye-34 CDR1 amino acid sequence

AASGRTFSRFAMG

35 **SEQ ID NO: 67 C-Ye-34 CDR2 amino acid sequence**

AISWSGGMIYYTDSVKG

SEQ ID NO: 68 C-Ye-34 CDR3 amino acid sequence

AVDTRNVIGPRAGDY

5

SEQ ID NO: 69 C-Ye-34 VHH amino acid sequence

QVQLQESGGGLVQAGGSLRLSCAASGRTFSRFAMGWFRQAPGKEREFVAAISWSG
GMIYYTDSVKGRFTISRDNAMLYLQMNSLKPEDTAVYYCAVDTRNVIGPRAG
DYWGQGTQVTVSS

10

SEQ ID NO: 70 C-Ye-34 VHH nucleotide sequence

CAGGTGCAGCTGCAGGAGTCTGGGGGAGGATTGGTGCAGGCTGGGGGCTCTCT
GAGACTCTCCTGTGCAGCCTCTGGACGCACTTTCAGTAGGTTTGCCATGGGCTG
GTTCCGCCAGGCTCCAGGGAAGGAGCGTGAGTTTGTAGCCGCTATTAGCTGGA
15 GTGGTGGTATGATATACTATACAGACTCCGTGAAGGGCCGATTCACCATCTCCA
GAGACAACGCCAAGAACATGCTGTATCTGCAAATGAACAGCCTGAAACCTGAG
GACACGGCCGTTTATTACTGTGCAGTCGATACGAGGAATGTAATCGGCCCAAG
AGCGGGAGACTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCAGT

20 **SEQ ID NO: 71 C-Ye-39 CDR1 amino acid sequence**

GRAFSVYPMA

SEQ ID NO: 72 C-Ye-39 CDR2 amino acid sequence

RLTYTSNTFYADSVKG

25

SEQ ID NO: 73 C-Ye-39 CDR3 amino acid sequence

AVENRSSSWSLQSPARYDD

SEQ ID NO: 74 C-Ye-39 VHH amino acid sequence

30 QVQLQESGGGLVQAGGSLRLSCTASGRAFSVYPMAWFRQAPGKEREFARLTYTS
NTFYADSVKGRFTISRDNAMNTVYLQMNSLKPEDTAVYYCAVENRSSSWSLQSPA
RYDDWGQGTQVTVSS

SEQ ID NO: 75 C-Ye-39 VHH nucleotide sequence

CAGGTGCAGCTGCAGGAGTCTGGGGGAGGATTGGTGCAGGCTGGGGGCTCTCT
 GAGACTCTCATGTACAGCCTCTGGACGCGCCTTCAGTGTCTACCCCATGGCCTG
 GTTCCGCCAGGCTCCAGGGAAGGAGCGTGAGTTTATAGCACGTCTTACGTATA
 CTAGTAACACATTCTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAG
 5 ACAACGCCAAGAACACGGTGTATCTGCAGATGAACAGCCTGAAACCTGAGGAC
 ACGGCCGTTTATTACTGTGCGGTCGAGAACCGCAGTAGTAGTTGGTCCCTGCAA
 AGCCCGGCACGTTATGATGACTGGGGCCAGGGGACCCAGGTCACCGTCTCCAG
 T

10 **SEQ ID NO: 76 C-Ye-42 CDR1 amino acid sequence**
 GRTGSRVAVG

SEQ ID NO: 77 C-Ye-42 CDR2 amino acid sequence
 AITWSGGYTTYADSVKG

15 **SEQ ID NO: 78 C-Ye-42 CDR3 amino acid sequence**
 AVDTRNVIGPRAGDY

SEQ ID NO: 79 C-Ye-42 VHH amino acid sequence
 20 QVQLQESGGGLVQAGGSLRLSCAASGRTGSRVAVGWFRQAPGLGRDFVAAITWS
 GGYTTYADSVKGRFTISRDNKNTMYLQMNSLKPEDTAVYYCAVDTRNVIGPRA
 GDYWGQGTQVTVSS

SEQ ID NO: 80 C-Ye-42 VHH nucleotide sequence
 25 CAGGTGCAGCTGCAGGAGTCTGGAGGAGGATTGGTGCAGGCTGGGGGCTCTCT
 GAGACTCTCCTGTGCAGCCTCTGGACGCACCGGCAGTAGGTATGCCGTGGGCT
 GGTTCCGCCAGGCTCCAGGGCTGGGGCGTGACTTTGTAGCAGCTATTACCTGGA
 GTGGTGGTTACACATACTATGCGGACTCCGTGAAGGGCCGATTCACCATCTCCA
 GAGACAACGCCAAGAACACGATGTATCTGCAAATGAACAGCCTAAAACCTGAA
 30 GACACGGCCGTTTATTACTGTGCAGTCGATACGAGGAATGTAATCGGCCCAAG
 AGCGGGAGACTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCAGT

SEQ ID NO: 81 C-Ye-18-1 CDR2 amino acid sequence
 SINSGSSSTYYRDSVKG

35 **SEQ ID NO: 82 C-Ye-18-1 VHH amino acid sequence**

EVQLQESGGGLVQPGGSLRLSCAASGFTFSSYWMYWLRQAPGKGLEWVSSINSGS
SSTYYRDSVKGRFTISRDNKNTLYLQMNSLKSEDTAVYYCAKDPGGYAKGQGT
QVTVSS

5 SEQ ID NO: 83 C-Ye-18-1 VHH nucleotide sequence

GAGGTGCAGCTGCAGGAGTCTGGAGGAGGCTTGGTGCAGCCTGGGGGGTCTCT
GCGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTACTGGATGTATTG
GCTCCGTCAGGCTCCAGGGAAGGGGCTCGAGTGGGTCTCATCTATTAATAGTG
GTAGTAGTAGCACATACTATCGAGACTCCGTGAAGGGCCGATTCACCATCTCC
10 AGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGTCTGAAATCTGA
GGACACGGCCGTGTATTACTGTGCAAAAGATCCTGGTGGGTACGCCAAAGGCC
AGGGGACCCAGGTCACCGTCTCCAGT

SEQ ID NO: 84 C-Ye-18-2 CDR2 amino acid sequence

15 SISSSSSSTYYRDSVKG

SEQ ID NO: 85 C-Ye-18-2 VHH amino acid sequence

EVQLQESGGGLVQPGGSLRLSCAASGFTFSSYWMYWLRQAPGKGLEWVSSISSSS
STYYRDSVKGRFTISRDNKNTLYLQMNSLKSEDTAVYYCAKDPGGYAKGQGTQ
20 VTVSS

SEQ ID NO: 86 C-Ye-18-2 VHH nucleotide sequence

GAGGTGCAGCTGCAGGAGTCTGGAGGAGGCTTGGTGCAGCCTGGGGGGTCTCT
GCGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTACTGGATGTATTG
25 GCTCCGTCAGGCTCCAGGGAAGGGGCTCGAGTGGGTCTCATCTATTAGTAGTA
GTAGTAGTAGCACATACTATCGAGACTCCGTGAAGGGCCGATTCACCATCTCC
AGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGTCTGAAATCTGA
GGACACGGCCGTGTATTACTGTGCAAAAGATCCTGGTGGGTACGCCAAAGGCC
AGGGGACCCAGGTCACCGTCTCCAGT

30

SEQ ID NO: 87 C-Ye-18-3 CDR2 amino acid sequence

SIGSSSSSTYYRDSVKG

SEQ ID NO: 88 C-Ye-18-3 VHH amino acid sequence

35 EVQLQESGGGLVQPGGSLRLSCAASGFTFSSYWMYWLRQAPGKGLEWVSSIGSSS
SSTYYRDSVKGRFTISRDNKNTLYLQMNSLKSEDTAVYYCAKDPGGYAKGQGT
QVTVSS

SEQ ID NO: 89 C-Ye-18-3 VHH nucleotide sequence

GAGGTGCAGCTGCAGGAGTCTGGAGGAGGCTTGGTGCAGCCTGGGGGGTCTCT
 GCGACTCTCCTGTGCAGCCTCTGGATTACCTTCAGTAGCTACTGGATGTATTG
 5 GCTCCGTCAGGCTCCAGGGAAGGGGCTCGAGTGGGTCTCATCTATTGGTAGTA
 GTAGTAGTAGCACATACTATCGAGACTCCGTGAAGGGCCGATTACCATCTCC
 AGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGTCTGAAATCTGA
 GGACACGGCCGTGTATTACTGTGCAAAAGATCCTGGTGGGTACGCCAAAGGCC
 AGGGGACCCAGGTCACCGTCTCCAGT

10

SEQ ID NO: 90 C-Ye-18-4 CDR2 amino acid sequence

SIYSGSSSTYYRDSVKG

SEQ ID NO: 91 C-Ye-18-4 VHH amino acid sequence

15 EVQLQESGGGLVQPGGSLRLSCAASGFTFSSYWMYWLRQAPGKGLEWVSSIYSGS
 SSTYYRDSVKGRFTISRDNKNTLYLQMNSLKSEDTAVYYCAKDPGGYAKGQGT
 QVTVSS

SEQ ID NO: 92 C-Ye-18-4 VHH nucleotide sequence

20 GAGGTGCAGCTGCAGGAGTCTGGAGGAGGCTTGGTGCAGCCTGGGGGGTCTCT
 GCGACTCTCCTGTGCAGCCTCTGGATTACCTTCAGTAGCTACTGGATGTATTG
 GCTCCGTCAGGCTCCAGGGAAGGGGCTCGAGTGGGTCTCATCTATTTACAGTG
 GTAGTAGTAGCACATACTATCGAGACTCCGTGAAGGGCCGATTACCATCTCC
 AGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGTCTGAAATCTGA
 25 GGACACGGCCGTGTATTACTGTGCAAAAGATCCTGGTGGGTACGCCAAAGGCC
 AGGGGACCCAGGTCACCGTCTCCAGT

SEQ ID NO: 93 C-Ye-18-5 CDR2 amino acid sequence

SINSDSSSTYYRDSVKG

30

SEQ ID NO: 94 C-Ye-18-5 VHH amino acid sequence

EVQLQESGGGLVQPGGSLRLSCAASGFTFSSYWMYWLRQAPGKGLEWVSSINSDS
 SSTYYRDSVKGRFTISRDNKNTLYLQMNSLKSEDTAVYYCAKDPGGYAKGQGT
 QVTVSS

35

SEQ ID NO: 95 C-Ye-18-5 VHH nucleotide sequence

GAGGTGCAGCTGCAGGAGTCTGGAGGAGGCTTGGTGCAGCCTGGGGGGTCTCT
 GCGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTACTGGATGTATTG
 GCTCCGTCAGGCTCCAGGGAAGGGGCTCGAGTGGGTCTCATCTATTAATAGTG
 ACAGTAGTAGCACATACTATCGAGACTCCGTGAAGGGCCGATTCACCATCTCC
 5 AGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGTCTGAAATCTGA
 GGACACGGCCGTGTATTACTGTGCAAAAGATCCTGGTGGGTACGCCAAAGGCC
 AGGGGACCCAGGTCACCGTCTCCAGT

SEQ ID NO: 96 C-Ye-18-6 CDR2 amino acid sequence

10 SINSGSSSTYYRDSVKG

SEQ ID NO: 97 C-Ye-18-6 VHH amino acid sequence

EVQLQESGGGLVQPGGSLRLSCAASGFTFSSYWMYWLRQAPGKGLEWVSSISGSS
 SSTYYRDSVKGRFTISRDNKNTLYLQMNSLKSEDTAVYYCAKDPGGYAKGQGT
 15 QVTVSS

SEQ ID NO: 98 C-Ye-18-6 VHH nucleotide sequence

GAGGTGCAGCTGCAGGAGTCTGGAGGAGGCTTGGTGCAGCCTGGGGGGTCTCT
 GCGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTACTGGATGTATTG
 20 GCTCCGTCAGGCTCCAGGGAAGGGGCTCGAGTGGGTCTCATCTATTAGTGGA
 GTAGTAGTAGCACATACTATCGAGACTCCGTGAAGGGCCGATTCACCATCTCC
 AGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGTCTGAAATCTGA
 GGACACGGCCGTGTATTACTGTGCAAAAGATCCTGGTGGGTACGCCAAAGGCC
 AGGGGACCCAGGTCACCGTCTCCAGT

25

SEQ ID NO: 99 IgG1 Fc fragment amino acid sequence

DKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
 WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
 APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ
 30 PENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL
 SLSPG

SEQ ID NO: 100 fusion protein linker amino acid sequence

GGGGSGGGSGGGGSGGGGSG

35

SEQ ID NO: 101 TGF β RII extracellular domain amino acid sequence

IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEK

PQEVCAVWRKNDENITLETVCHDPKLPYHDFILEDAAAPKCMKEKKKPGETFFM
CSCSSDECNDNIIFSEEYNTSNPD

SEQ ID NO: 102 PM8001 amino acid sequence

5 EVQLQESGGGLVQPGGSLRLSCAASGFTFSYWMYWLRQAPGKGLEWVSSINSDS
SSTYYRDSVKGRFTISRDNKNTLYLQMNSLKSIEDTAVYYCAKDPGGYAKGQGT
QVTVSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV
10 NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHY
TQKSLSLSPGGGGGSGGGGSGGGGSGGGGSGIPPHVQKSVNNDMIVTDNNGAVKF
PQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCAVWRKNDENITLETVCHD
PKLPYHDFILEDAAAPKCMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD

15 **SEQ ID NO: 103 upstream primer for first round**

GTCCTGGCTGCTCTTCTACAAGG

SEQ ID NO: 104 downstream primer for first round

GGTACGTGCTGTTGAACTGTTCC

20

SEQ ID NO: 105 upstream primer for second round

CTAGTGCGGCCCGC_cTGGAGACGGTGACCTGGGT

SEQ ID NO: 106 downstream primer for second round

25 CGCGGATCCCAGGTGCAGCTGCAGGAGTCTGGRGGAGG

SEQ ID NO: 107 upstream primer for third round

ATTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTAAAAGAGAGGCT
GAAGCACAGGTGCAGCTGCAGGAGTCTGGRGGAGG

30

SEQ ID NO: 108 downstream primer for third round

AGTTGTCAGTTCCTGTGCCCCCCTCCTCCCGCGCCACCTCCGCCCCGCACCTCC
GCCACCA_cTGGAGACGGTGACCTGGGT

35 **SEQ ID NO: 109 PD-L1-His tag amino acid sequence**

MFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEE
DLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRIT
VKVNAPYHHHHHH

5 SEQ ID NO: 110 PD-L1 single-domain antibody fusion protein amino acid sequence

EVQLQESGGGLVQPGGSLRLSCAASGFTFSSYWMYWLRQAPGKGLEWVSSINSDS
SSTYYRDSVKGRFTISRDNANKNTLYLQMNSLKSSEDVAVYYCAKDPGGYAKGQGT
QVTVSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVVS
10 NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHY
TQKSLSLSPG

SEQ ID NO: 111 PD-L1 single-domain antibody amino acid sequence

15 EVQLQESGGGLVQPGGSLRLSCAASGFTFSSYWMYWLRQAPGKGLEWVSSINSDS
SSTYYRDSVKGRFTISRDNANKNTLYLQMNSLKSSEDVAVYYCAKDPGGYAKGQGT
QVTVSSDK

CLAIMS

What is claimed is:

1. A complementarity determining region (CDR) of a VHH chain of an anti-PD-L1 single-domain antibody, wherein the CDR of the VHH chain consists of the following:

5 CDR1 with an amino acid sequence as shown in SEQ ID NO: 5n+1;

CDR2 with an amino acid sequence as shown in SEQ ID NO: 5n+2, or CDR2 with an amino acid sequence having a sequence identity of greater than 85% with a sequence as shown in SEQ ID NO: 2; and

CDR3 with an amino acid sequence as shown in SEQ ID NO: 5n+3;

10 wherein, each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.

2. A VHH chain of an anti-PD-L1 single-domain antibody, wherein the VHH chain of the anti-PD-L1 single-domain antibody comprises the CDR1, CDR2 and CDR3 according to claim 1.

15 3. The anti-PD-L1 single-domain antibody according to claim 2, wherein the amino acid sequence of CDR2 is shown in SEQ ID NO: 93.

4. An anti-PD-L1 single-domain antibody, wherein the anti-PD-L1 single-domain antibody is a single-domain antibody against a PD-L1 epitope and has the VHH chain of the anti-PD-L1 single-domain antibody according to claim 2.

20 5. The anti-PD-L1 single-domain antibody according to claim 2, wherein an amino acid sequence of the VHH chain of the anti-PD-L1 single-domain antibody is shown in SEQ ID NO: 94.

25 6. A polynucleotide, wherein the polynucleotide encodes a protein selected from the group comprising the CDR region of the VHH chain of the anti-PD-L1 single-domain antibody according to claim 1, the VHH chain of the anti-PD-L1 single-domain antibody according to claim 2, or the anti-PD-L1 single-domain antibody according to claim 4.

7. A single-domain antibody fusion protein, wherein the single-domain antibody fusion

protein has a structure as shown in formula I from N-terminal to C-terminal:

Z1-Z2-L-Z3 (Formula I)

wherein,

Z1 is the VHH chain of the anti-PD-L1 single-domain antibody according to claim 2;

5 Z2 is an Fc fragment of immunoglobulin;

L is a linker sequence; and

Z3 is an immunoregulatory molecule part.

8. The single-domain antibody fusion protein according to claim 7, wherein an amino acid sequence of the single-domain antibody fusion protein is shown in SEQ ID NO: 102.

10 9. An immunoconjugate, comprising:

(a) the VHH chain of the anti-PD-L1 single-domain antibody according to claim 2, the anti-PD-L1 single-domain antibody according to claim 4, or the single-domain antibody fusion protein according to claim 8; and

15 (b) a coupling moiety selected from the group comprising detectable markers, drugs, toxins, cytokines, radionuclides or enzymes.

10. Use of the anti-PD-L1 single-domain antibody according to claim 4 or the single-domain antibody fusion protein according to claim 8 in manufacture of (a) reagents used for detecting PD-L1 molecules; and (b) drugs used for treating tumors.

11. A pharmaceutical composition, comprising:

20 (i) the CDR of the VHH chain of the anti-PD-L1 single-domain antibody according to claim 1, the VHH chain of the anti-PD-L1 single-domain antibody according to claim 2, the anti-PD-L1 single-domain antibody according to claim 4, the single-domain antibody fusion protein according to claim 7, or the immunoconjugate according to claim 9; and

(ii) a pharmaceutically acceptable carrier.

25 12. Use of the VHH chain according to claim 2, the single-domain antibody according to claim 4, the single-domain antibody fusion protein according to claim 5 or the

immunoconjugate according to claim 9 in manufacture of medicaments, reagents, detection plates or kits;

wherein, the reagents, the detection plates or the kits are used for detecting a PD-L1 protein in a sample; and

- 5 wherein, the medicaments are used for treating or preventing tumors expressing the PD-L1 protein (PD-L1 positive).




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15

Effect of PM8001 on tumor volume of h-PD-L1 KI MC38 in
h-PD-L1 KI C57BL/6 mice




FIG. 16




FIG. 17




FIG. 18




FIG. 19

Effect of PM8001 and M7824 on the tumor growth of h-PD-L1 KI MC38
tumor cell in h-PD-L1 KI C57BL/6 mice




FIG. 20




FIG. 21

Effect of PM8001 and M7824 on the tumor weight of h-PD-L1 KI MC38 tumor cell in h-PD-L1 KI C57BL/6 mice




FIG. 22

Effect of PM8001 and M7824 on the body weight of h-PD-L1 KI C57BL/6 mice inoculated with h-PD-L1 KI MC38 tumor cell




FIG. 23

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2020/058303

A. CLASSIFICATION OF SUBJECT MATTER

C07K 16/28(2006.01)i; A61K 39/395(2006.01)i; C12N 15/13(2006.01)i; A61P 35/00(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K; A61K; C12N; A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CNABS,DWPI,SIPOABS,CNTXT,WOTXT,USTXT,EPTXT,CNKI,PUBMED,ISI WEB OF SCIENCE:single domain antibody, VHH, PD-L1, CD274; EMBL+GenBank+Retrieve System of Biological Sequence of Chinese Patent: Sequence search of SEQ ID NOs.11-15.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CN 107849130 A (SUZHOU KANGNING JIERUI BIOTECHNOLOGY CO et al) 27 March 2018 (2018-03-27) see the abstract and claims 1, 12, 16, 17	1-12
A	CN 110003333 A (SHENZHEN PREGENE BIOPHARMACEUTICAL CO LTD) 12 July 2019 (2019-07-12) see the whole document	1-12
A	WO 2019096121 A1 (NANJING LEGEND BIOTECH CO LTD) 23 May 2019 (2019-05-23) see the whole document	1-12
A	LV G et al. "PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody" <i>Journal of nuclear medicine</i> , Vol. 6, No. 1, 28 June 2019 (2019-06-28), ISSN: 1535-5667, Pages 117-122, see the whole document	1-12



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 December 2020

Date of mailing of the international search report

15 January 2021

Name and mailing address of the ISA/CN

National Intellectual Property Administration, PRC
6, Xitucheng Rd., Jimen Bridge, Haidian District, Beijing
100088
China

Facsimile No. (86-10)62019451

Authorized officer

ZHANG,Dandan

Telephone No. 62411308

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2020/058303

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	IEZZI ME et al. "Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment" <i>Frontiers in immunology</i> , No. 9, 19 February 2018 (2018-02-19), ISSN: 1664-3224, Pages 1-11, see the whole document	1-12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2020/058303**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☒ No protest accompanied the payment of additional search fees.

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- [1] Invention 1, claims 1, 2, 4, 6-7 and 9-12(all partial), directed to VHH chain or single domain antibody comprising all 3 CDRs of C-Ye-02, and corresponding polynucleotide, fusion protein, immunoconjugate, pharmaceutical composition and related use;
- [2] Invention 2, claims 1, 2, 4, 6-7 and 9-12(all partial), directed to VHH chain or single domain antibody comprising all 3 CDRs of C-Ye-04, and corresponding polynucleotide, fusion protein, immunoconjugate, pharmaceutical composition and related use;
- [3] Invention 3, claims 1, 2, 4, 6-7 and 9-12(all partial), directed to VHH chain or single domain antibody comprising all 3 CDRs of C-Ye-06, and corresponding polynucleotide, fusion protein, immunoconjugate, pharmaceutical composition and related use;
- [4] Invention 4, claims 1, 2, 4, 6-7 and 9-12(all partial), directed to VHH chain or single domain antibody comprising all 3 CDRs of C-Ye-17, and corresponding polynucleotide, fusion protein, immunoconjugate, pharmaceutical composition and related use;
- [5] Invention 5, claims 1, 2, 4, 6-7, 9-12(all partial) 3, 5 and 8, directed to VHH chain or single domain antibody derived from C-Ye-18, and corresponding polynucleotide, fusion protein, immunoconjugate, pharmaceutical composition and related use;
- [6] Invention 6-14, claims 1, 2, 4, 6-7 and 9-12(all partial), directed to VHH chain or single domain antibody comprising all 3 CDRs of C-Ye-20, C-Ye-24, C-Ye-26, C-Ye-27, C-Ye-30, C-Ye-32, C-Ye-34, C-Ye-39 or C-Ye-24, and corresponding polynucleotide, fusion protein, immunoconjugate, pharmaceutical composition and related use;
- [7] It is well established in the art that the three CDRs of variable region provide the majority of the contact residues for the binding of the single domain antibody to its target epitope. The amino acid sequences and conformations of each of the CDRs are critical in maintaining the antigen binding specificity and affinity which is characteristic of the parent single domain antibody. The same or corresponding technical feature among inventions 1-14 is that the single domain antibody is specifically binded to human PD-L1. For a person skilled in the art, the antibody specifically binded to human PD-L1 is known in the prior art, such as D1 (CN107849130 A, 27.03.2018) discloses a single domain antibody for human programmed death-ligand (PD-L1) (see the abstract). Therefore, the 14 inventions related to human PD-L1 single domain antibody do not share a same or corresponding special technical feature that makes a contribution over the prior art. Above all, unity of invention is lacking and thus does not meet the requirements of Rule 13.1, 13.2.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/IB2020/058303

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)			Publication date (day/month/year)
CN	107849130	A	27 March 2018	RU	2018107427	A	28 August 2019
				HK	1252955	A1	06 June 2019
				HK	1251591	A1	01 February 2019
				CN	111116747	A	08 May 2020
				CA	2994339	A1	09 February 2017
				AU	2016302951	B2	10 October 2019
				KR	20180033582	A	03 April 2018
				RU	2018107427	A3	28 August 2019
				MX	2018001387	A	15 August 2018
				EP	3330290	A4	28 August 2019
				KR	102138447	B1	28 July 2020
				WO	2017020802	A1	09 February 2017
				CN	107849130	B	31 December 2019
				PH	12018500233	A1	13 August 2018
				US	2018291103	A1	11 October 2018
				WO	2017020801	A1	09 February 2017
				EP	3348571	A4	10 April 2019
				EP	3330290	A1	06 June 2018
				CN	107636013	B	31 December 2019
				RU	2715595	C2	02 March 2020
				CN	106397592	A	15 February 2017
				EP	3348571	A1	18 July 2018
				JP	2018531039	A	25 October 2018
				AU	2016302951	A1	22 February 2018
				CN	107636013	A	26 January 2018
				NZ	739499	A	25 October 2019
				BR	112018002130	A2	11 September 2018
				US	2018327494	A1	15 November 2018
				JP	2018529375	A	11 October 2018
CN	110003333	A	12 July 2019	None			
WO	2019096121	A1	23 May 2019	TW	201923083	A	16 June 2019
				CN	111433224	A	17 July 2020
				AU	2018366650	A1	21 May 2020
				CA	3081375	A1	23 May 2019